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ABSTRACT 
The purpose of this study is to gain better understanding of the ligating 
properties of D N A from a theoretical and structural perspective. The D N A models 
are geometry optimized using Restricted Hartree Fock theory (RHF) and their 
comparisons of the experimental results demonstrate the qualitative acceptability of 
RHF. Results obtained from ab initio calculation show that the Highest Occupied 
Molecular Orbital (HOMO) is localized on the guanine (G) in the G-containing 
sequences. It suggests that G forms the most active site in G-containing sequences. 
Ab initio results also reveal that the location of the next Highest Occupied Molecular 
Orbital (HOMO-1) is sequence dependent. A set of empirical selection rule is 
proposed to locate the H O M O and its nearby active site, leading to postulation of 
cisplatin-DNA crosslinks. The formation of the crosslink adducts are discussed 
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Deoxyribonucleic Acid (DNA) is a well-known genetic material which 
controls the heredity and metabolism of an organism. It bears a variety of 
secondary and tertiary structures depending upon the conditions, e.g. double stranded 
helices, hairpins, bulges, branched junctions, two-dimensional lattices, 
three-dimensional cubes and octahedrons (1.1，1.2). Many diseases result because 
of malfunction, mutation and damage of DNA, as a consequence of changes in its 
shape and conformation (1.3). Therefore, recognizing the chemical properties and 
structure characteristics of D N A certainly provides insights into biological functions 
of nucleic acids. 
1.2 Deoxyribonucleic Acid 
The terms used, atom numbering schemes and abbreviations recommended 
by the Commissions of the International Union of Pure and Applied Chemistry 
(lUPAC) (1.4) and organized by Wolfram Saenger (1.3) were followed to describe 
the structure and geometry of the DNA, are defined. 
1.2.1 Nomenclature and Symbols 
D N A is a double helix and a polymeric species in the Watson-Crick model 
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(1.5). The basic repeating unit is the nucleotide, which consists of a deoxyribose 
sugar, a heterocycle and a phosphate linkage group (Figure 1.1). The four 
heterocycles are the purine bases adenine (A) and guanine (G) and the pyrimidine 
bases thymine (T) and cytosine (C) (Figure 1.2). They are held together by 
hydrogen bonds to form the complementary base pair, whereby A pairs with T and C 
with G (Figure 1.3). Also, there is a phosphodiester bond linkage between two 
sugar rings to give the sugar-phosphate backbone. 
In the backbone, atoms in the sugar are distinguished from that of the base by 
a prime. And the atoms of a polynucleotide backbone and sugar in the sequence are 
counted starting from P ~> O5’ — C5’ — C4’ -> C3’ -> O3’ P(n+i) and Ci’ C2’ 
C3, C4’ "•> O4，Ci, respectively, where (n+1) indicates the atom of the next 
nucleotide (Figure 1.1). 
0 = P — — c v 
尸/-Base 
广 c . i 
O3 
Figure 1.1 The Nucleotide 
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Figure 1.3 The Base-Pairs of D N A 
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1,2,2 Torsion A ngles 
Following the numbering sequence, the torsion angles of the sugar-phosphate 
backbone, namely a, P，y, 5，s, ‘ and vo, Vi, V2, V3, V4, as well as the orientation of 
the base x，are defined as shown in Figure 1.4. On the other hand, the endocyclic 
torsion angles of sugar give rise to another term, the pseudorotation phase angle P 
[1-1]. Values of phase angles from 0° to 360° are given in multiples of 36° and 
hence ten conformations are included (Figure 1.5). 
tanP 二（… ) - ( V 3 + v。) 
2v2(sin36。+SIN720) L J 
� 
y O O X 
广 \9-Base = 
^ V ^ i 
e O 
4 。 - ^ ^ B a s e 
. a [ t ^ 
V X o 
C ^ B a s e = 
〇 
Figure 1.4 The Naming of the Torsion Angles of D N A Backone and Sugar Ring 
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1 ±180^  
々 ’ I 
Figure 1.5 Definition of the Pseudorotation Angle (1.4) 
1.2.3 Conformation 
In general, D N A is divided into three categories, right-handed A- and 
B-forms, and left-handed Z-form (Figure 1.6) (1.1). The Waston-Crick structure is 
referred to as the B-form DNA, which is the most stable form under physiological 
conditions. 
Apart from the conformation of the sugar ring, the helical parameters are 
utilized to describe the geometry of nucleic acids. There are 16 defined parameters 
according to the E M B O workshop (1.6). They are the inclination (rj), tip (d), 
buckle (K)’ propeller twist (co), opening (a), tilt (r), roll (p), and twist (fi) in the 
rotational mode, and the x displacement (dx), y displacement (dy), shear (Sx), stretch 
-5-
(Sy), stagger (Sz), shift (Dx), slide (Dy) and rise (Dz) in the translational mode 
(Figure 1.7). 
T纛1蜃: 
' 1 1 1 
A form B form Z form � 
Figure 1.6 The A, B, and Z forms of D N A (1.1) 
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Figure 1.7 Definition of the Helical Parameters 
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1.3 DNA Studies 
DNA, the genetic information repository, is a stable biomacromolecule. Its 
three-dimensional structure was delineated by Waston and Crick in 1953 (1.5). The 
unique structure plays important roles in biomolecular processes with many other 
forms of conformation revealed since then (1.1). Thus investigation on the variety 
of D N A conformation is important in understanding the expression of genetic code, 
D N A metabolism, DNA-drug interaction and etc. An enormous body of 
experimental and theoretical data had been reported over the years (1.2, 1.3，1.7). 
The experiments are often carried out using X-Ray and N M R , and sometimes 
theoretical studies are also carried out after obtaining the structure coordinates from 
experiments. 
1.3.1 Base 
Among the four bases, G is found to be the most easily oxidized (1.8, 1.9). 
Also its ionization potential (IP) is the lowest (Table 1.1)，therefore it is most 
electron donating (1.10, 1.11). In the presence of oxidants and/or under U V 
irradiation, G radical cation (G+ •) would be ultimately produced to form 
8-oxoguanine (or dihydro-8-oxoguanine) (Figure 1.8)，(1.12-1.14) which leads to 
mutation during replication (1.15). The positive charge then migrates to G-rich 
position in the sequence (Figure 1.9) (1.15-1.20) because G-rich sequence is much 
- 8 -
more electronegative, as demonstrated by the lower IP values of GG and GGG 
compared with that of a single G (Table 1.1) (1.10，1.21，1.22). 
Table 1.1 Ionization Potential ofN-Methylated Nucleobase Monomers and 
Stacked Contiguous Guanines (eV) (1.10) 
Base G A C T G G G G G G G G G 
IP ( e V ) T ^ b ^ m ^ ^ ^ ^  
(0.47)* (0.68)* (0.77)* 
* The value in parentheses is the difference from the IP of nonstacked guanine 
U H X 
Y 人 N 人 N H , 1 人 八 H 2 
Guanine 8-oxo-guanine 
Figure 1.8 Guanine and 8-Oxo-Guanine 
mutational 
� hot spot ^ 
離 》 
y^^oxldatkjn^ y < z electron, V ^ 
% 一 备 - 备 
Figure 1.9 Oxidation of G and Charge Transfer to G G (1.15) 
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For a G-rich sequence, the 5' G is more electronegative than the 3’ end. 
This effect has been revealed from a theoretical study demonstrating that the H O M O 
of stacked 5'-GG is largely localized on 5’ G (1.11, 1.13，1.23). However, for the 
special case ofTGGGT, M O analysis indicates that the centre G was found to be the 
most reactive (1.24). It is suggested that the sequence dependent effect influences 
the reactivity of the D N A (1.25, 1.26). 
1.3.2 Base-Pair 
The complementary bases are held together by hydrogen bonding (Figure 
1.3). The H-bonds reinforce each other and reduce the net buildup of charge on 
bases (1.27). Besides the weak interaction, proton transfer in G-C base-pair has 
been shown to exist, which can be promoted by the oscillatory contraction motion of 
D N A (1.28). The positive charge of G+ • could be stabilized by proton transfer 
between G-C base-pair, (1.29) thus it was believed that the proton-transfer process 
contributes to the electron and hole transfer in DNA. 
Connection of base-pairs results in stacking, which is sensitive to the 
oxidative damage (1.30). Experiments also show that the number of bridging A-T 
base pair affects the rate of charge transfer (1.31). 
When a charge is transferred to a remote G-site from G+ • along the sequence, 
biological damage and mutation is expected to happen (1.15). The concept of 
- 1 0 -
sacrificial cathodic protection has been proposed as a means of protecting genes 
from being oxidized (1.32). 
1.3.3 Summary 
Oxidative damage and G-rich sequence are important in biological system, 
whereby the reactivity and the sequence pattern are related. Especially, G plays a 
key role in mechanism of D N A damage. Drug design to treat genetic diseases can 
be targeted towards the reactivity of D N A bases. Understanding the structural and 
electronic properties of D N A is expected to assist in the recognition of the biological 
targets. 
1.4 Cisplatin Studies 
Cisplatin or cis-diamminedichloroplatinum (II) is a platinum complex with 
I 
two amines and two chlorides (abbreviated as CDDP) (Figure 1.10a). It is a widely 
used anti-cancer drug that has been particularly successful in treating small cell 
lung, ovarian, testicular, head, and neck tumors. On the other hand, its trans 
isomer, transplatin (Figure 1.10b), cannot form 1,2-intrastrand adducts, so that it is 
clinically ineffective. However treatments are often complicated by development 
of nephrotoxicity and the emergence of drug-resistant (1.25, 1.26). 
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H3N z C I H3N z。丨 
� t /Pt 
H3N \。1 c r NH3 
(a) (b) 
Figure 1.10 (a) Cisplatin and (b) Transplatin 
1.4.1 Reaction 
Cisplatin specifically binds to N7 of purines (Figure 1.2)，（1.33) where the 
electronegative N is preferred by the platinum (II) center and enhances the binding 
(1.34). The chlorides are readily displaced through hydrolysis. Binding with the 
N7 of the purines followed (see Figure 1.11) (1.35-1.37). H-bonds were formed 
from the bound chloride to the solvated ion in aquation, increasing the occurrence of 
the substitution reaction, and reducing the destacking of nucleobases (1.38). 
Moreover, the ratio of the rate constant of binding on 5' to that on 3’ (ks'/ks-) 
of d(-TGGT-) sequence are 0.18 for single-strand and 0.32 for the duplex, which 
imply that the binding is more rapid at the 3, (1.39, 1.40). When binding with 
sequence containing an A G step, the rate constant for binding to the 3，-G is 1.06 土 
0.06 and to the 5'-A is 0.149 士 0.014 M'^ s'V These results confirm again that 
the platination on 3‘ position (G) is faster than that on 5' (A) (1.41). Thus the 
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Figure 1.11 The Binding Process of Cisplatin to D N A 
The chelation is enhanced by the structural properties of the purines which 
have strong affinity for Pt (1.42-1.44). The electron density is concentrated on the 
N7 by withdrawing electron from C8 on the purines (1.45). Moreover, G is 
preferred over A in cisplatin binding as the N7 lone pair in G is much more intense, 
(1.46) and that binding to G is also thermodynamically favoured (1.47). 
The platination strengthens the bond of the G-C base pair (1.48). The 
binding energy of C at G increases by strengthening the attraction of the negative 02 
and N3 sites at C and G (Figure 1.3) (1.49). Conversely, the base pair would be 
-13 -
weakened if the H-bond in cisplatin is broken upon the formation of a bidentate 
N7-06 complex with guanine (1.50). 
1.4.2 Cisplatin-DNA Products 
Platination to two purines gives the DNA-adducts with intrastrand and 
interstrand crosslinks. Experimentally, the intrastrand of 1,2-d(GpG) and 
1.2-d(ApG) products are the most frequently occurred. The intrastrand 
1.3-d(GpXpG) and the interstrand d(GpC)d(GpC) products were also reported, 
whereas 1，2-d(GpA) adduct was not found (1.45, 1.51-1.53). The ligation of 
cisplatin to two adjacent purines was determined to be 65% for the intrastrand of 
l,2-d(GpG) and 22% for the l，2-d(ApG) products (1.54). Binding of cisplatin had 
been shown to take place on the A of the 5' side of d(ApGpA) (1.55). It has been 
suggested that the failure to observe cisplatin-GA binding is due to the slow 
monofunctional binding of cis-[PtCl(NH3)2(OH2)]+，whereby the binding is the 
slowest when compared to that of G G or A G (1.41). 
Since any crosslink formed produces structural distortion on the sequence, 
(1.38，1.56, 1.57) thus the intrastrand G X G bends and unwinds the D N A sequence 
more than G G and A G (1.58). The bending and unwinding of D N A duplex resulted 
from formation of crosslinks with Pt lead to cell death by suppressing the 
transcription of D N A , (1.59) thus the antitumor property (1.60-1.63). Despite 
-14-
bending and unwinding, the intermolecular H-bonds between bases are flilly 
retained. 
The bend cisplatin-DNA adduct is recognized by a family of small 
recognition proteins H M G which either stabilize the distorted D N A structure or 
remove the lesion through repair. The proteins bound to the l，2-d(GpG) intrastrand 
adduct, but not to the 1，3-d(GpTpG). Thus the repair of the 1,2-intrastrand 
crosslink could be inhibited and not the 1,3-intrastrand (1.64-1.67). 
1.4.3 Summary 
The antitumor activity of cisplatin is known to result from binding to D N A . 
Ligation of D N A to platinum results in structural distortion of D N A , where the 
degree of bending is sequence dependent. The major products observed are the 
intrastrand l,2-d(GpG) and l，2-d(ApG) adducts, and with minor portion of 
intrastrand l,3-d(GpXpG) and interstrand d(GpC)d(GpC) adducts. 
1.5 Scope of This Thesis 
The main theme of this work is to theoretically investigate the structure and 
the electronic properties of DNA, and its ligating properties towards cisplatin, as 
well as to determine the factors controlling the formation of the binding products. 
A large number of studies have been published on both D N A base-pairs and 
cisplatin biological chemistry. In order to obtain a clear picture of the biological 
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process involved, better understanding of the interaction between DNA and cisplatin 
is necessary. 
While many theoretical studies had been carried out on nucleotide, single 
base pair and base-pair stacking of D N A (1.68). There are relatively few studies 
reporting theoretical investigation of several base-pairs including the sugar-
phosphate backbone. To obtain a more complete understanding on the ligating 
property of D N A towards platinum anticancer drugs, ah initio study on the structure 
and its electronic properties analysis on D N A base-pairs with the backbone is taken 
into consideration in this work. 
In this study, a series of short segment D N A s are analyzed. They are double 
stranded 5'-GX-3', 5，-AX-3，，5'-XGG-3', 5，-GGX-3，，5’-GXG-3，，5，-XAG-3’， 
5'-AXA-3 ’ and 5，-XGGX-3 ’ (where X = A,T, C and G). All components of the 
base-pairs will be taken into consideration so as to provide a better description and 
analysis of the system. As we know, the major products of cisplatin-DNA compose 
of the purine bases, G and A. The models chosen are thus formed from the 
combination of these two bases, G and A. The optimized geometries and their 
electronic characteristics were studied using ab initio method. Restricted 
Hartree-Fock (RHF) theory with the minimal basis set ST0-3G was applied to the 
geometry optimization and the molecular orbital calculation (1.69). 
-16-
CHAPTER T W O 
COMPUTATION AND METHODOLOY 
2.1 Introduction 
Quantum mechanics describes the behaviour of the electrons and nuclei of 
atoms and molecules, whereas quantum chemistry applies quantum mechanics to the 
study of problems in chemistry. Nowadays, many computer-based softwares had 
been developed and the usage is not only limited in chemistry. Finding and 
describing an appropriate approximation is a preoccupation to quantum mechanical 
calculation (2.1，2.2). 
2.2 Hartree-Fock (HF) Approximation 
HF calculation is the most common type of ab initio calculation and is based 
on average electron-electron interaction. The Coulombic electron-electron 
repulsion is taken into account by integrating the repulsion term. This is a 
variational calculation, where the approximate energies calculated are all equal to or 
greater than the exact energy. 
In the theory, the energy has the form (2.3): 
EHF ~ Enuclear + Ecore + Ecoulomb + Eexchange [2-1 ] 
where the terms have the following meanings: 
Enuclear IS the nuclcar repulsion energy, 
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Ecore is the one-electron (kinetic plus potential) energy, 
Ecouiomb is the classical coulomb repulsion of the electrons, and 
Eexchange IS the exchange energy resulting from the quantum (fermion) nature 
of electrons. 
In the R H F method, both a and p electrons in each pair use the same orbital 
spatial function. That is the electrons are paired up and the molecule is singlet in 
spin. What is more，HF is suitable for qualitative description of large system 
(2.4-2.6). 
In addition, a basis function is required to express the individual molecular 
orbital and the most popular minimal basis set, ST0-3G, consists of expansions of 
Slater-type atomic orbitals (STOs) in terms of three gaussian functions. 
2.3 Geometry Optimization 
The D N A models 5’-GX-3，，5'-AX-3', 5'-XGG-3', 5，-GGX-3，，5，-GXG-3，， 
5’-XAG-3，，5'-AXA-3' and 5'-XGGX-3'(where X = A,T,C and G, Figure 1.2) in 
B-form double helical structure were studied. They were constructed in the form of 
neutral molecule using S Y B Y L 6.2 (2.7) in which the ends and the phosphates on the 
backbone were terminated with protons (Figure 2.1). Full geometry optimization 
were performed using Guassian 98 (2.8) and Guassian 03 (2.9) programmes at 
RHF/ST0-3G level of theory using PC clusters and workstations. 
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Figure 2.1 Models of 2, 3 and 4 Base Pairs 
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2.4 Molecular Orbital (MO) Calculation 
To elucidate the electronic property of the DNA, the Highest Occupied 
Molecular Orbital (HOMO) and the next Highest Occupied Molecular Orbital 
(HOMO-1) of the optimized structures were located with RHF/STO-3G using 
Gaussian 03 and Gauss View 3.09. 
2.5 Verification of Methodology 
In general utilizing higher level of theory and basis set would result in more 
accurate description of the chemical system under investigation. However the 
computation effort could become unreasonable, particularly when the system is large. 
Therefore it is necessary to balance improved accuracy using high level theory 
versus qualitative prediction using a lower level method. In this study, a primitive 
level was used for geometry optimization and M O calculation and the resulted 
torsion angles and bond distances were compared with experimental data. 
2.5.1 Backbone Torsion Angles 
The sugar-phosphate backbone torsion angles of the optimized three 
base-pair structure, 5'-GGG-3', were compared with the experimental results 
obtained from the Nucleic Acids Database (NDB) (2.10). Structures of 47 
sequences determined using X-ray (2.11) and 12 sequences determined using N M R 
(2.12) contained the G G G sequence were extracted for comparison. (Appendices I 
- 2 0 -
and II) 
It was found that all the torsion angles of 5，-GGG-3，，except for the epsilon 8 
(Figure 1.4) of the third base, i.e. 3，G，match the experimental data (Figure 2.2). 
This angle deviates the most from the experimental data. The disagreement is 
attributed to the terminal fraying effect because the base-pair will become more 
flexible due to less restriction and hence a greater angle variation is obtained. 
When the sequence is extended to contain four guanine-cytosine base pairs, the e of 
the third base-pair of G G G G falls back within the range of the standard deviation 
(79.97。for N M R ; 30.55。for X-Ray) of the experimental data of 5，-GGG-3，(Figure 
2.3). The backbone torsion angles of the fourth G of 5'-GGGG-3' show drastic 
deviation when compared with the experimental data (Figure 2.4). Three sequences 
determined by N M R (2.13) and twelve sequences determined by X-Ray (2.14) were 
extracted from the NDB. The deviation is predictable as the base is positioned at the 
terminal, where the base is influenced by the terminal end fraying effect. Therefore, 
longer base-pair model is expected to provide a better simulation of D N A units. 
Moreover, since the 5' side of a D N A sequence is more electron-rich (2.15, 
2.16), a stronger interaction would result. For this reason, it is suggested that 
end-fraying occurs at the 3' end but not the 5’ end, as the 3' end produces weaker 
chelation. 
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Figure 2.2 Comparison of Backbone Torsion Angles of Computed and 
Experimental 5'-GGG-3' 
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Figure 2.3 Comparison of Backbone Torsion Angles of Computed 5'-GGGG-3' 
and Experimental 5'-GGG-3' 
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2.5.2 N7-N7 Distance 
A reference distance, N7-N7 distance of two adjacent guanines, was 
measured for the optimized structures GG, G G G and G G G G (Table 2.1). The inter 
base-pair distance of the first X-Ray photographs of fibrous D N A was 3.4 人（2.17). 
It is expected that the average calculated N7-N7 distance of G G (6.35 人)，GGG 
(5.55 A) and G G G G (4.95 A) would be longer than the standard 3.4 A and the 
average experimental value (4.23 A) of N M R and X-Ray data (Table 2.1). Since 
base-pairs are held together more tightly and less degree of freedom are allowed 
when additional base-pairs are stacked-on, therefore the inter base-pair distance 
decreases with increasing number of base-pair. 
The calculated reference distance (rd) is expected to decrease and approach 
the real value when the number of base-pair (n) increased (Figure 2.5). The value 
for the length of the sequence is predicted from the reference distance difference 
(Ard) of the 2, 3 and 4 base pairs (Table 2.2). 
n = 2 n = 3 n = 4 
I L,.,., ...... I L .......I I 
'' rd4 
^ rd3 i V , 
rd2 i V ；—ArS：—I I 
、， — A : ; — I ‘ — t — 、 ( rd4 
丨 I— rd3 I \ I 
^： , 、rd4 
I I V 
I I 
Figure 2.5 Schematic Diagram of the Reference Distances of Base-Pairs 
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Table 2.1 N7-N7 Distance of the Optimized Structure of GG, GGG and GGGG, 
and the Experimental Structures with Terminated 5'-GGG-3' 
一N7-N7 Distance/A G(1)-G(2) G(2)-G(3) G⑶-G⑷ Average^  
Calculated GG 6.35 - - 6.35 
Calculated GGG 5.54 5.55 -- 5.55 
Calculated GGGG 5.39 4.16 5.29 4.95 
NMRb 4.62(0.57)。 4.08(0.71)。 -- 4.35 
X-Rayd 4.18(0.42)。 4.12 (0.51)。 -- 4.15 
Average of NMR&X-Ray 4.28(0.46)。 4.17(0.52)。 - ^  
a Average value of G(1 )-G(2). G{2)-G(3) and G(3)-G(4) 
b NDB ID: 
1. 169D-GGGTATACGC 
2. 1J5N- GGGGTGATTGTTCAG 
3. 1LFU-GGGCAATCATGCGC 
c The value in bracket showing the standard deviation 
d NDB ID: 
1. PD0024 - GGGAAGCATATGCTTCCC 
2. PD0030 - GGGCGCCGTGGTC 
3. PD0033 - GGGCGCCGTGGTC 
4. PD0112- GGGCGCCTATAAAAGGGG 
5. PD0222 - GGGTTTAAAGAAATTCCAGA 
6. PD0393 - GGGGGGGCTATAAAAGG 
7. PD0504 - GGGGGAAGGATTC 
8. PD0505 - GGGGAAGGATTCA 
9. PDE003-GGGATATCCC 
The difference between the rd (Ard = rdn-i — rdn) for the sequences containing 
2 and 3 base pairs is 0.8 人 and that containing 3 and 4 base pairs is 0.6 A. A 
scaling factor of 0.75 is derived from the ratio of Ard4 / Ard�（0.6/0.8). The 
difference of the predicted reference distance (Ardp) can be found using 0.75Ardn-i. 
Then the predicted reference distance (rdp) is determined from rdn-i. 
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For example, when n = 5, 
Ardp = ArcU x (0.6/0.8) = 0.75Ard4 = 0.75 x 0.6 = 0.45 
rdp 二 rd4 — Ardp = 4.95 - 0.45 = 4.5 
The distances with n = 5，6，7， 20 were predicted based on the 
procedures giving above. The results are summarized in Table 2.2 and Figure 2.6. 
From the predicted results, an inter base-pair distance of 6 base pairs (n = 6) of 4.16 
A is expected to fit the average value of 4.23 人 listed in Table 2.1. This average 
value will be employed throughout the following discussion. So model systems 
with a minimum of six base pair would give a better description of the structural 
parameter of DNA. 
Furthermore, the predicted distance of 3.33 A for 12 base-pairs (n= 12) 
surprisingly matches the mean rise distance (3.33 A) of the dodecamer 
d ( C G C G A A T T C G C G ) as shown in Table 2.3. Also, the predicted distance (3.39 A) 
with 11 base pairs (n = 11) almost equals to the stacked distance of B D N A (3.38 人). 
Therefore model with twelve base-pairs would be the best representation of B D N A . 
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Table 2.2 The Calculated and Predicted Reference Distance 
Calculated Predicted 
"n rd/A Arda/A Ardp^ /A rdpC/A 
2 6.35 - -- -
3 5.55 0.8 -- --
4 4.95 0.6 -- --
5 - -- 0.45 4.50 
6 - - 0.34 4.16 
7 - -- 0.25 3.91 
8 - - 0.19 3.72 
9 - - 0.14 3.58 
10 -- -- 0.11 3.47 
11 - - 0.08 3.39 
12 - - 0.06 3.33 
13 - - 0.05 3.29 
14 - - 0.03 3.25 
15 -- - 0.03 3.23 
16 - -- 0.02 3.21 
17 - - 0.01 3.19 
18 - - 0.01 3.18 
19 - -- 0.01 3.17 
20 -- - 0.01 3.17 
NMR & X-Rayd 4.23 
a Ard = rdn-i - rdn 
b Ardp = Ard x (0.6/0.8) = 0.75Ardn-i 
c rdp = rdn-i - Ardp 
d Average value of NMR and X-Ray from Table 2.1 
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Figure 2.6 Plot of the Calculated and Predicted Reference Distance 
Table 2.3 Rise for the B-DNA Dodecamer d(CGCGAATTCGCG) (2.18) 
Base-pairs Rise per base pair/A Base-pairs Rise per base pair/A 
^ ^ 
• 3.38 土 0.08 T = 314士002 
C3/G22 C9/G16 ^ … 
3.26 士 0.05 3.56 ±0.07 
G4/C21 G10C15 ^ ^ 
3.30 士 0.10 3.21 土 0.18 八5斤20 … … C11/G14 … … 
3.27 土 0.02 3.54 土 0.19 
A6/T19 … … G12/C13 
3.31 ±0.03 
T7/A18 Mean 3.33 ±0.13 
BDNA ^ 
2.5.3 Location of HOMO 
To demonstrate the credibility of locating the MO using RHF/ST0-3G, 
H O M O findings of experimental 2 base-pair models from Protein Data Bank (PDB) 
(2.19，2.20) were compared with those calculated using DFT (2.21). The base-pairs 
of AG, GA, G G and A A were calculated using a higher level of theory, UB3PW91/ 
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(2.19，2.20) were compared with those calculated using DFT (2.21). The base-pairs 
of AG，GA, G G and A A were calculated using a higher level of theory, UB3PW91/ 
6-311G(d，p) (Figure 2.7). 
The shape of H O M O s obtained using UB3PW91/6-3 llG(d,p) are more 
diffuse than that using RHF/ST0-3G For G G and AA, although there is charge 
distribution over the stacked bases using UB3PW91 /6-311 G(d,p), location of the 
majority of electron cloud can be predicted using RHF/ST0-3G. The sharing of 
electron cloud will be discussed in Chapter 3.7.1. In spite of the difference in the 
shape of the H O M O results obtained by the two methods, the major position is 
obtained using RHF/ST0-3G. Therefore, results from both theories confirm the 
same position for the H O M O , implying that a less vigorous method, RHF, is 
appropriate for qualitative determination of M O location. 
2.6 Summary 
By comparing the computed and experimental data of the backbone torsion 
angles, the reference distances, as well as the location of H O M O s using DFT theory, 
it is concluded that all calculation at RHF/ST0-3G can qualitatively represent the 
electronic structure of D N A . Therefore, the method is acceptable for a qualitative 
analysis of D N A . 
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Base-Pair RHF/ST0-3G UB3PW91/6-311G(d.p) 
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Figure 2.7 Location of H O M O of 2 Base-Pair Models Computed by HF and DFT 
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CHAPTER THREE 
UNDERSTANDING OF THE CISPLATIN-DNA CROSSLINKS 
3.1 Introduction 
Cisplatin binds to the purines bases of D N A (3.1-3.3) to exert its anticancer 
activity. Recently molecular orbital (MO) analysis method had been applied to the 
study of biological system. For examples, the charge transfer (3.4, 3.5), hydrogen 
bonding (3.6) in D N A , and the interaction of platinum (II) complex (3.7). In this 
study, M O calculation method was employed in determining (i) the binding products 
of cisplatin-DNA, and (ii) the structural investigation of the D N A models from a 
theoretical perspective. 
3.2 MO Analysis 
In the ligand substitution reaction, the Highest Occupied Molecular Orbital 
( H O M O ) of the ligand interacts with the Lowest Occupied Molecular Orbital 
(LUMO) of the substrate (3.8). In the case of cisplatin-DNA binding, the ligating 
properties of D N A can be illustrated in the same way. It is expected that the 
electrons of H O M O from guanine (G) donate to the L U M O of cisplatin (Figure 3.1). 
The location of the H O M O therefore refers to the most active site in a D N A 
sequence, and that of the next Highest Occupied Molecular Orbital (HOMO-1) refers 
to the next active site accordingly. In this study, the H O M O and H O M O - 1 of short 
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DNA sequences were located and a rationalization is put forth to account for the 
binding products. 
A 
^ H3N " , C I 
G m ) ^ pt 
H3N \ CI 
u 
Figure 3.1 Electron Donation from H O M O of Guanine to L U M O of Cisplatin 
3.5 Potential Binding Sites on DNA 
The H O M O is found at G for theoretical models of any G-containing D N A 
sequence. Thus G is the most reactive among the four bases where the electrons are 
located and depart from the system easily. This observation is supported by the 
ionization potential (IP) of G, being the smallest among the four bases (2.9). The 
possible binding sites to cisplatin can be pinpointed from the location of the H O M O 
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Figure 3.2 The Location of H O M O and HOMO-1 of the Base-pair Models, and 
the Possible Crosslink to Cisplatin 
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Figure 3.2 The Location of H O M O and H O M O - 1 of the Base-pair Models, and 
the Possible Crosslink to Cisplatin 
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(e) d(GpXpC)d(GpXpC) Interstrand Crosslink (cont'd) 
H O M O HOMO-1 
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Figure 3.2 The Location of H O M O and HOMO-1 of the Base-pair Models, and 
the Possible Crosslink to Cisplatin 
3J. 1 l,2-d(GpG) Intrastrand Crosslink 
The M O calculation results of the models GG, AGG, TGG, GGA, GGT, 
AGGA, G G G G and TGGT showed that the H O M O s and HOMO-1 s were located on 
two adjacent Gs (Figure 3.2a). The two sites with most electrons localized served 
as binding sites to cisplatin. 
3.3.2 l,2-d(ApG) Intrastrand Crosslink 
The H O M O s of A Q A A G and AG A were located at G. Also HOMO-1 s 
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were found on adjacent 5'A of the H O M O - G for A G and AGA. For the case of 
AAG, although there is shared distribution of HOMO-1 electrons on the two A, the 
electrons on the second A, which is adjacent to G, still have probability to take part in 
the 1,2-AG crosslink formation (Figure 3.2b). 
3.3.3 1,3-d(GpXpG) Intrastrand Crosslink 
For GGG, G T G and GAG, the H O M O and HOMO-1 were found on the first 
and third G, two M O s together responsible for the 1,3-GXG intrastrand crosslink 
(Figure 3.2c). 
3.3.4 d(GpC)d(GpC) Interstrand Crosslink 
In the case of GC，CGG and CGGC, the H O M O was located on a G, and the 
H O M O - 1 was on the nearest G on the complementary strand. For C G G the 
H O M O - 1 distributes over two G，however the majority of the electron cloud was 
positioned at the second G, sitting opposite to the neighbour of the H O M O - G (Figure 
3.2d). From these results, an interstrand crosslink is thus possible. 
3.3.5 d(GpXpC)d(GpXpC) Interstrand Crosslink 
The H O M O and H O M O - 1 were located at the two 5'Gs of the 3 base pairs, 
G G C and CAG. A d(GpXpC)d(GpXpC) interstrand crosslink can then be formed 
diagonally across the two M O s (Figure 3.2e). 
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3.3.6 Summary 
There are five types of possible crosslinks obtained from the M O analysis. 
The results of the location of H O M O and HOMO-1 for each model are summarized 
in Figure 3.3. 
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Figure 3.3 Summary of Location of H O M O and HOMO-1 of D N A Base Pairs 
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(cont'd) 
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Figure 3.3 Summary of Location of H O M O and H O M O - 1 of D N A Base Pairs 
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3.4 Empirical Selection Rule 
Based on the results obtained from the 2, 3 and 4 base pairs, a set of 
empirical "Selection Rule" is proposed allowing the H O M O and the nearby active 
site to be located. These predicted active sites are compared with experimentally 
determined binding sites obtained from experimental Pt bound sequences extracted 
from the Protein Data Bank (PDB) (2.10). 
3.4.1 Convention 
To begin the analysis, a site identification convention is given to the system 
(Figure 3.4). For a double helix d(X2X,ZYi Y2)d(Y2’Yi，Z’Xi’X2，)，strand II is 
complementary to strand I. X i and Yi are the adjacent neighbours of Z; X2 and Y2 
are the next adjacent neighbours of Z; Xi ‘ and Yi，are the nearest neighbours of Z; 
X2' and Y2’ are the next nearest neighbours of Z. 
Adjacent to Z Next adjacent to Z 
u 
I： 5,- X2 Xi Z 丫1 丫2 -3' 
II: 3'- X2,Xi,Z, 丫1,丫2' -5' 
Nearest to Z Next nearest to Z 
Figure 3.4 Site Identification Convention 
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3.4.2 Selection of Potential HOMO Location (or Active Site) 
According to the results of M O analysis, it was found that the H O M O is 
always located on G (Figure 3.3). Therefore, for any sequence containing only one 
G, the H O M O is simply located on G. For sequences containing more than one G, a 
set of rules is observed in choosing the target G, i.e. the G containing H O M O . The 
procedures are summarized in Table 3.1. 
Table 3.1 Procedure in Locating a H O M O on a D N A Sequence 
Selection of Potential HOMO Location (or Active Site) 
I. HOMO at G for sequence containing only one G 
II. HOMO also at G for sequence containing more than one G, it can be located by 
following the priority and step outlined 
Step Detail Examples 
1 Identify G without G or A as adjacent neighbour TGGCAA ACATGA 
ACCGTT TGTACT 
2 For G(s) with nearest A simultaneously, identify G of 3’ TTGGTT TGTGTG 
position AACCAA ACACAC 
3 Identify G without A as the nearest neighbour TGGCTT ATGGGTA 
ACCGAA TACCCAT 
4 Identify G without A as the next adjacent neighbour TTGGTA TTGTGTA 
AACCAT AACACAT 
5 For G with adjacent A, identify G without A as the next AAGGAT AAGTGAT 
nearest neighbour TTCCTA TTCACTA 
6 Identify G of 5，on the same strand AAGGAA AAGAGAA 
TTCCTT TTCTCTT 
-45 -
As shown above, for sequence containing more than one G, the first step is to 
obtain a G without any adjacent neighbour G or A. If no suitable G can be 
recognized, then identify G of 3' position for G(s) with nearest A simultaneously, 
Step 2. If G remains unclassified, follow, Step 3, that is to get a G without a nearest 
neighbour A. In Step 4, locate a G without a next adjacent neighbour A. For G 
with an adjacent A, choose the G without A as the next nearest neighbour, Step 5. 
The G of 5' on the same strand is identified at last, Step 6. Examples are provided 
to illustrate the case in each step. 
With this set of established empirical rule, H O M O is always found to locate 
on G for any G-containing sequence. From the M O results of CGG, G G C and C A G 
models (Figure 3.3), the H O M O is first located on the G where there is no nearby 
purine base by inspection. So that Step 1 is given. This is logical for the 
H O M O - G to be away from another electronegative species like A. The IP of A 
(8.24 eV) is slightly higher than that of G (7.75 eV) (Table 1.1) indicating the 
relative lower electronegativity of A compared to G (3.9). Neighbouring with 
another purine might result in a competition for electrons. 
Moreover, G on the 5' side is believed to be more reactive in general (3.9， 
3.11). When a H O M O is located on 5，G of the stacked GG, more electron donation 
is expected. On the contrary, when G is on the 3’ side, more electron donation 
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would be expected when there is a nearest neighbour A. The M O results of G T G 
and T G G T substantiate the observation (Figure 3.3). Futhermore, platination of 
cisplatin is experimentally shown to be preferred on 3’-G in a d(-TGGT-) sequence 
(3.12, 3.13) as supported by the ratio of the reaction rate constants of ks-Zka- (Figure 
1.11)，which was found to be 0.18 for single-strand and 0.32 for the duplex. 
Therefore the computed results are in agreement with the experimental data. Hence, 
the scenario that H O M O at 3' is plausible verified. 
3.4.3 Selection of Potential HOMO-Nearby Active Site 
After categorizing the active site, the potential binding site to cisplatin can 
then be identified by positioning the HOMO-nearby active site. The detailed 
procedure is shown in Table 3.2. The crosslink is produced from the H O M O and its 
nearby active site. 
The 1,2-GG intrastrand crosslink can be formed when there is an adjacent G 
of the HOMO-G, whereas d(GpC)d(GpC) interstrand crosslink can be produced from 
the H O M O - G and its nearest G. The next adjacent and next nearest Gs of 
H O M O - G are responsible for the 1,3-GXG intrastrand and d(GpXpC)d(GpXpC) 
interstrand crosslinks respectively. On the other hand, when the H O M O is on a G 
with a 5'A preceding it, the 1,2-AG intrastrand crosslink can be obtained. 
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Table 3.2 Procedure in Locating a HOMO-Nearby Active Site on a DNA Sequence 
Selection of the Potential HOMO-Nearby Active Site  
Step Detail Example Resulted crosslink  
1 Identify the adjacent G of HOMO-G T T ^ T T 1,2-GG intrastrand 
AACCAA 
2 Identify the nearest G of HOMO-G TCGCTC d{GpC)d(GpC) interstrand 
AGCGAG 
3 Identify the next adjacent G, next TGTGAA 1,3-GXG intrastrand 
nearest G of HOMO-G ACACTT  
TGTCAG d(GpXpC)d(GpXpC) interstrand 
ACAGTC 
4 Identify the 5'A adjacent to A ^ T A T 1,2-AG intrastrand 
HOMO-G TTCATA 
3.4.4 Applications 
Sequences from the PDB and literature results, which had shown binding 
with cisplatin, were chosen to demonstrate the rule (Table 3.3). According to the 
rule stated in Tables 3.1 and 3.2，the experimental binding sites were recognized. 
For example, the sequence 1A2E, there are seven Gs, one on strand I and six 
on strand II. The G on strand I is chosen because it has no adjacent G or A as stated 
in Step 1 of the rule. This G and the fifth G counting from 5' of strand II gives a 
d(GpC)d(GpC) interstrand crosslink. For the sequence 1A84, all Gs on both 
strands bear adjacent purines, so step 1 cannot identify the target G. According to 
step 2，the 3' G of 5'-(TGGT)-3' on strand I is chosen, where the two consecutive Gs 
have nearest A simultaneously. That G and its adjacent 5 ’ G then give rise to a 
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Table 3.3 Comparison of the Predicted versus Experimental Binding Position of 
GG in the Formation of Cisplatin Binding Adducts 
(a) PDB strand Sequence (5'-xxx-3') N7(G)-N7(G) 
ID Experimental result Predicted binding site distance/A 
1 1A2E [ 1 ] 
(X-ray) I CCTCGCTCTC CCTCGCTCTC 2.75* 
II GGAGCGAGAG ^AGCGAGAG 4.66 
[2] 
2 1A84 [ 1 ] 
(NMR) I CCTCT 因 TCTCC CCTCT 翌 TCTCC 2.90* 
II GGAGACCAGAGG GGAGACCAGAGG 4.69； 4.90 
[3] [2] 
3 1AI0 [ 1 ] 
(X-ray) I C C U C T ^ T C T C C C C U C T ^ T C T C C 2.89*’ 2.92* 
II GGAGACCAGAGG ^ A G A C C A G A ^ 4.06,3.88; 4.14,4.19 
[3] [2] 
4 1AU5 [ 1 ] 
(NMR) I C C T ^ T C C C C T ^ T C C 2.73* 
II GGACCAGG 翌 A C C A竺 4.20； 4.85 
[3] [2] 
5 1CKT [ 1 ] 
(X-ray) I CCUCTCT^ACCTTCC CCUCTCT^ACCTTCC 2.72* 
I I GGAGAGACCTGGAAGG ^AGAGACCTGGAA^ 4.27; 3.48； 3.69 
[4] [2] [3] 
6 1DDP 
(NMR) I CATAGCTATG CATAGCTATG 2.90* 
II GTATCGATAC GTATCGATAC 
7 1I1P [ 1 ] 
(X-ray) I CCTCGCTCTC CCTCGCTCTC 2.74* 
II GGAGCGAGAG ^AGCGAGAG 4.62 
[2] 
8 1KSB [ 1 ] 
(NMR) I CTCCGGCCT C T C C ^ C C T 2.81* 
II GAGGCCGGA GA^CCGGA 3.69； 4.08 
[2] [3] 
Number with square bracket [ ] indicates the priority; asterisk (*) refer to cisplatin bound distance 
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(cont'd) 
(b) strand Sequence (5'-xxx-3') 
Reference 
Experimental result Predicted binding site 
1 
I TATGCATA TATGCATA 
— - (3.14) 
“II ATACGTAT ATACGTAT 
2 [2] 
I TATGGCAT TATGGCAT 
— (3.14) 
II ATACCGTA ATACCGTA 
[1] 
3 
I TATGGTAT TATGGTAT 
— (3.14) 
II ATACCATA ATACCATA 
4 [1] 
I ...CTGTGCA... ...CTGTGCA... 
—— - - (3.15) 
II ...GACACGT... ...GACACGT... 
[2] 
5 
I CTCTCGGTCTC CTCTCGGTCTC 
— (3.16) 
II GAGAGCCAGAG GAGAGCCAGAG 
6 
I ATACATGGTACATA ATACATGGTACATA 
一 (3.17) 
II TATGTACCATGTAT TATGTACCATGTAT 
7 
I ATGGGT ATGGGT 
— 一 (3.18) 
II TACCCA TACCCA 
Number with square bracket [ ] indicates the priority. 
1,2-GG intrastrand crosslink. Similarly the predicted binding sites for the other 
sequences were obtained. The N7-N7 distance of adjacent Gs is also listed. 
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3.5 Cisplatin 
Cisplatin (CDDP) and cisplatin-HaO (CDDP-H2O) were modeled and 
geometry optimized with RHF/ST0-3G and RB3LYP/LANL2DZ. The optimized 
details were shown in Table 3.4 and Figure 3.5. 
Table 3.4 Optimized Cisplatin and Cisplatin-HzO with Basis Set L A N L 2 D Z Using 
Different Levels of Theory m N ^N,^   
X2\ > � 
X _ _ ！ _ _ _ M _ _ ^ H 、 Pti H” 
cisplatin CI CI / I N*、 N5 
cisplatin-H20 0 CI H / H , 、 h / 、 ’ 。 
cisplatin cisplatin-H20 
RB3LYP B m RB3LYP S m 
Energy/Hartree -262.30 -262.43 -323.52 -323.63 
Bond Distance/A 
PtiX2 2.41 2.41 2.11 2.11 
PtiYs 2.41 2.41 2.38 2.38 
PtiN4 2.11 2.10 2.12 2.12 
PtiNs 2.11 2.10 2.05 2.04 
N4H6 1.02 1.03 1.03 1.03 
N4H7 1.02 1.03 1.03 1.03 
N4H8 1.03 1.05 1.03 1.04 
N5H9 1.02 1.03 1.03 1.03 
N5H10 1.03 1.05 1.03 1.04 
N5H11 1.02 1.03 1.03 1.03 
X2M12 - - 0.98 0.99 
X2M13 - -- 0.98 0.99 
Bond Angle/0 
X2PtiY3 96.72 96.90 90.10 90.30 
Y3PtiN4 178.71 178.20 176.58 176.40 
X2PtiN5 178.71 178.20 175.95 175.70 
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！ 19.3 3.60 96.7 ^ j j T 
(a) Cisplatin (b) Cisplatin-HaO 
Figure 3.5 Diagrams of Optimized (a) Cisplatin and (b) Cisplatin-HzO at 
RB3LYP/LANL2DZ Level of Theory 
S. 6 Cisplatin-DNA Crosslinks 
Although there are five kinds of possible crosslinks, not all of them may have 
potential for formation and only four had been identified experimentally. They are 
the l,2-d(GpG), l,2-d(ApG) and l,3-d(GpXpG) intrastrand as well as the 
d(GpC)d(GpC) interstrand crosslink adducts (3.19-3.21). The details of the 
crosslinks are discussed below. 
3.6.1 1，2-d(GpG) and l，2-d(ApG) Intrastrand Crosslinks 
The H O M O and H O M O - 1 were located on the adjacent purines. The 
stacked base-pair distance of 3.4 A reported by Astury's (3.22) and Wilkins，(3.23) 
X-Ray data of D N A fits the chloride to chloride distance, r(Cl-0H2), of 3.19 A of the 
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optimized cisplatin-HzO (Figure 3.5). Also the donor orbital was predicted at N7 of 
purines (3.24) for platination. Thus the binding to cisplatin is feasible. 
3.6.2 l,2-d(ApG) versus l,2-d(GpA) Intrastrand Crosslinks 
Experimentally, the A G adduct was found but not the G A adduct (3.25). 
From the M O result of 5’-AGA-3，，the H O M O is located at G, and there are two As 
for the H O M O - 1 to be located with one on the 5' side and one on the 3’ with respect 
to the HOMO-G. Based on the M O result obtained, the H O M O - 1 was found on the 
5，A but not on the 3’A (Figure 3.2b), so that an A G intrastrand crosslink is preferred 
rather than GA. Experimentally, binding of cisplatin had also been shown to take 
place on the A of the 5' side of d(ApGpA) (3.26). 
Moreover, the energies of the H O M O of the optimized 2 base pairs A G 
is 一0.192 in Hartree whereas that of G A is -0.170, and the L U M O energy of the 
cisplatin is 0.096 Hartree. All energies were computed with RHF/ST0-3G except 
for the platinum of the cisplatin in which the basis set L A N L 2 D Z was used. 
Accordingly A G is relatively more stable than G A and will form a more stable 
product with cisplatin (Figure 3.6). These results therefore explain why only 
AG-adduct was found. 
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Figure 3.6 Schematic M O Diagram of the AG- and GA-Cisplatin Binding 
3.6.3 l’3-d(GpXpG) Intrastrand and d(GpXpC)d(GpXpC) Interstrand Crosslinks 
The N7-N7 distances of the l,3-d(GpXpG) intrastrand and the 
d(GpXpC)d(GpXpC) interstrand crosslinks were much more longer than the 
r(Cl-0H2) of 3.19 A (Table 3.5). Even though a distance of 6.8 A [2 x 3.4 A based 
on Astury's (3.21) and Wilkins' (3.22)] was predicted for a double stacked base-pairs, 
it remains much longer than 3.19 A. The distances of the models G G C and CAG, 
which show potential interstrand-binding to cisplatin, were measured and 
summarized in Table 3.5. Both the optimized and system-built distances are also 
longer than 3.19 A. Large structural distortion on D N A would be induced if 
binding with cisplatin occurs, (3.9, 3.11) which renders these crosslinks structurally 
less favourable. 
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Table 3.5 N7-N7 Distance ofG-G of the Optimized GGC and CAG 
Model G ^ C A G 
N7-N7 Distance/A Optimized 11.44 10.30 
S Y B Y L ^ 8.18 
3.6.4 Platination at Terminal Positions 
No cisplatin-DNA adduct was found at the terminal positions although the 
sequences contain G G or A G basepairs (Table 3.1). W e believe this observation 
could be attributed to the end fraying effect. The chelation of the cisplatin would 
become increasingly difficult because of the increase latitude of the "moving" 
nucleotides in the terminal position. A rationalization can be put forth through a 
comprehension of the effects of the backbone torsion angles. The torsion angles of 
the optimized G G G and G G G G were compared to the experimental data (Figures 3.7 
and 3.8). The sequences were obtained from the Nucleic Acid Database (NDB) 
(3.27) where all sequences terminated with G G G were collected (3.28). 
(Appendices I and II) The angles of the first base-pair deviate from the 
experimental results, both X-Ray and N M R data also fluctuate. However this 
circumstance did not exist for the second base-pair, confirming that the first 
base-pair is dynamically unstable. 
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Backbone Torsion Angles of Terminated 5'G(1) of5'-GGG-3' 
350 n 
霍 150 ’ r^c a . G G G l 
100 - 1 —A^nmr 
‘ X - r a y 
50 
0 I 1 ———' ‘ ‘ 
Y 6 e ^ X 
angle 
Backbone Torsion Angles of Terminated 5'G(2) of5'-GGG-3' 
350 1 
r \ 
® 150 ^ ^ - ^ c a l GGG 
100. X ^ ^ ^ — m r 
I x - r a y 
50 ^ ^ 
0 J" 1 > 1 —^  ‘ ‘ 
a P Y 6 £ 《 X 
angle 
Figure 3.7 Comparison of Backbone Torsion Angles of Computed 5, -GGG-3, and 
Experimental Sequences with Terminal 5，-GGG-3’ 
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Backbone Torsion Angles of Terminated 5'G(1) of 5'-GGG-3' 
350 n 
300 
% 150- 卜 calGGGG| 
100 J- " ^ n m r 
x-ray 
50 , , 
0 1 • • ‘ 
Y 6 £ ^ X 
angle 
Backbone Torsion Angles of Terminated 5'G(2) of5'-GGG-3' 
350 n 
300 ^ ^ 
” X 
I 150 ^ 卜 calGGGG 
1 ⑷ I 二 ： 
50 ^ ^ 
0 -1- 1 1 1 1 ‘ ‘ 
a P Y 6 £ S X 
angle 
Figure 3.8 Comparison of Backbone Torsion Angles of Computed 5，-GGGG-3, 
and Experimental Sequences with Terminal 5,-GGG-3’ 
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Moreover, as seen from the optimized structure of GGGG, the terminal G G 
on the 5，side was twisted and distorted (Figure 3.9a). The terminal G G G G of the 
experimental sequence PD0505 is also shown in Figure 3.9b. The distortion 
probably results in less favourable ligation because of misfitting of cisplatin. 
(a) hhi^ ibbihi^ HH 
H H I B H 
Figure 3.9 Structures of (a) Optimized G G G G and (b) Experimental G G G G from 
N D B PD0505 
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3.7 Structural Parameters 
In order to further understand the characteristics of DNA, the helical 
parameters of the optimized geometries and experimental sequences were analyzed 
with C U R V E S 4.1 (3.29-3.31). Analysis will be concentrated on the inter base-pair 
parameters among the 16 parameters, namely shift (Dx), slide (Dy), rise (Dz), tilt (r), 
roll (p) and twist (fi) (Figure 1.7). Furthermore the torsion angles of the 
sugar-phosphate backbone (a, (3, y, 5，8 and Q and the orientation of the base (x) 
(Figure 1.4), together with the sugar ring conformation of each structure were also 
studied. (Appendix I) 
3.7.1 Optimized Geometries 
Detailed results of the inter base-pair parameters for all optimized geometries 
are summarized in Table 3.6. The helical parameters of the 4 base pairs of A G G A , 
C G G C , G G G G and T G G T were graphically described as shown in Figure 3.10. 
Table 3.6 Inter Base Pair Parameters of the Optimized Geometries 
Base Pair Step Shift Slide Rise Tilt Roll Twist  
(Dx) (Dy) (Dz) (tau) (rho) (Omega) 
(AX,TX') 
(AAJT) A1/A2 1.20 0.16 5.02 6.94 -2.99 35.96 
(AGJC) A1/G2 0.10 -0.15 5.87 -1.65 0.77 25.01 
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(cont'd)  
Base Pair Step Shift Slide Rise Tilt Roll Twist 
(Dx) (Dy) (Dz) (tau) (rho) (Omega) 
(GX，CX，） 
(GA,CT) G1/A2 -0.13 -0.38 6.13 -3.36 -3.59 21.83 
(GC，GC) G1/C2 0.41 -0.86 5.37 1.07 1.20 26.68 
(GG，CC) G1/G2 0.41 -0.17 6.24 -0.94 -18.07 30.21 
(GT,AC) G1/T2 0.31 -0.64 5.83 1.15 -5.10 29.29 
(XGG.X'CC) 
(AGGJCC) A1/G2 0.10 0.10 5.18 -0.73 7.57 24.08 
G2/G3 -0.11 -0.09 5.36 1.28 -7.95 25.28 
(CGG,GCC) C1/G2 -1.18 1.04 4.51 -18.89 -6.76 37.92 
G2/G3 1.60 -1.44 3.64 -3.36 -13.72 11.63 
(GGG.CCC) G1/G2 0.08 0.13 5.40 -1.69 -3.49 27.00 
G2/G3 -0.10 -0.12 5.35 3.21 2.47 26.56 
(TGG,ACC) T1/G2 0.29 0.00 4.62 -1.06 12.54 27.15 
G2/G3 -0.27 -0.07 5.18 0.08 -10.01 28.51 
(GGX.CCX') 
(GGA，CCT) G1/G2 0.18 0.14 5.67 -1.76 0.64 27.93 
G2/A3 -0.19 -0.13 4.94 2.24 -1.46 25.81 
(GGC,CCG) G1/G2 0.01 0.24 5.31 -0.86 -13.05 25.44 
G2/C3 -0.02 -0.26 4.37 0.75 13.34 22.61 
(GGT，CCA) G1/G2 0.14 0.12 5.38 0.44 -1.11 24.67 
G2/T3 -0.15 -0.13 5.05 0.35 2.63 20.68 
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(cont'd)  
Base Pair Step Shift Slide Rise Tilt Roll Twist 
(Dx) (Dy) (Dz) (tau) (rho) (Omega) 
(GXG.CX'C) 
(GCG,CGC) G1/C2 0.02 -0.56 3.38 -4.03 8.48 28.44 
C2/G3 0.08 0.27 3.72 -3.32 -1.87 29.37 
(GTG.CAC) G1/T2 -0.07 -0.40 5.25 -0.46 3.56 25.14 
T2/G3 0.10 0.36 4.37 -1.36 -1.54 25.87 
(XAG.XTC) 
(AAGJTC) A1/A2 -1.05 0.32 4.34 -0.44 1.31 33.88 
A2/G3 1.05 -0.31 5.52 0.86 -1.49 25.26 
(CAG，CTC) C1/A2 -0.11 0.18 4.25 1.22 6.10 27.70 
A2/G3 0.13 -0.21 4.68 -2.73 -5.15 24.81 
(GAG，CTC) G1/A2 0.02 -0.23 4.90 1.33 3.21 24.72 
A2/G3 -0.02 0.23 4.91 -1.47 -3.10 25.11 
(TAG,CTC) T1/A2 0.00 0.01 4.47 -1.64 0.82 28.90 
A2/G3 0.06 -0.17 4.62 -2.29 4.88 24.38 
(AXA.TXT) 
(AAAJTT) A1/A2 0.10 0.01 4.73 -0.10 -0.70 25.90 
A2/A3 -0.08 -0.07 4.43 -1.19 2.87 23.46 
(AGAJCT) A1/G2 0.16 0.15 4.86 1.38 4.37 26.13 
G2/G3 -0.17 -0.15 5.19 -0.71 -4.50 27.06 
(XGGX,X'CCX') 
(AGGAJCCT) A1/G2 -0.01 0.05 4.77 -1.52 7.09 24.71 
G2/G3 0.04 -0.07 4.94 0.49 -2.72 23.21 
G3/A4 -0.09 0.05 4.84 0.93 0.32 24.16 
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(cont'd) 
Base Pair Step Shift Slide Rise Tilt Roll Twist 
(Dx) (Dy) (Dz) (tau) (rho) (Omega) 
(CGGC.GCCG) C1/G2 -0.13 0.60 3.98 -1.46 13.67 28.80 
G2/G3 0.05 -0.24 3.98 -3.36 -8.72 24.15 
G3/C4 -0.10 -0.41 3.72 0.63 11.49 22.61 
(GGGG.CCCC) G1/G2 1.88 -0.96 3.68 -1.37 -14.17 28.68 
G2/G3 -0.58 0.45 5.43 -3.47 11.23 29.11 
G3/G4 -0.03 0.10 4.87 -5.55 -4.18 28.49 
(TGGT,ACCA) T1/G2 -0.03 -0.04 4.94 -2.01 11.15 26.90 
G2/G3 0.08 0.15 4.95 0.34 0.72 22.65 
G3/T4 -0.19 -0.36 5.45 1.36 -5.80 21.65 
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(cont'd) 
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An average value for each base-pair step was determined from the computed 
base pairs structure (Table 3,7). From the observed values of the different 
parameters for the steps with different combination of bases, it is suggested that the 
structural features are sequence dependent. 
In general, steps involving the A and G bases were discovered to have large 
rise and twist values, indicating that larger repulsion would be induced as compared 
to other bases. The high electronegativity of A and G are confirmed from IP 
investigation study, (3.9) thus A A step carries the greatest twist value (29.80。)， 
whereas the greatest rise is found in A and G in G A (5.20 人). 
On the other hand, the average twist value of the A A step is 35.19° for the 
sequence 1G14, which was used for M O calculation in Chapter 2 (Table 3.8). This 
value is somewhat larger than the average value of 34.38°, suggesting that the degree 
of the twist affects the overlapping of the M O s of the stacked bases, hence sharing of 
electron cloud would result (3.9). To look into the M O overlapping, models AA, 
A A A and A G A were therefore studied. In section 2.5.3, the H O M O calculation for 
G G and A A using DFT method shows that electron distributes over the stacked bases, 
while it does not when using RHF (Figure 2.6). Again, the different degree of M O 
overlap explains this result. 
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Table 3.7 Summary of the Inter Base Pair Parameters of Computed Base-Pair Step 
Base-Pair Shift Slide Rise Tilt Roll Twist 
Step (Dx) (Dy) (Dz) (tau) (rho) (Omega) 
A/A 0.04 0.11 4.63 1.30 0.12 29.80 
A/G 0.21 -0.06 5.03 -1.06 1.05 25.06 
G/A -0.10 -0.17 5.20 0.29 -0.38 24.13 
G/C 0.06 -0.42 3.37 -0.32 6.90 20.07 
G/T -0.03 -0.38 5.40 0.60 -1.18 24.19 
G/G 0.20 -0.09 4.65 -1.17 -4.94 24.29 
C/G -0.31 0.48 3.05 -5.92 1.26 24.02 
T/A 0.00 0.01 2.24 -0.82 0.41 14.45 
T/G 0.12 0.11 4.64 -1.48 7.38 26.64 
To facilitate the analysis, rise values of the optimized geometries and the 
P D B sequence 1G14 are compared. The inter base-pair distance for the optimized 
2 base-pairs was determined to be greater than experimental data, which can be 
revealed from the average distances of 4.23 人（Table 2.1) and the rise values given 
in Table 3.8. For the two models A A and GG, the optimized rise are 5.02 人 and 
6.24 人 respectively，whereas the average distances of 1G14 are 2.95 A and 2.94 人 
respectively. A larger distance for the optimized geometry will result in relatively 
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poorer overlapping of MOs, hence electron cloud sharing is not observed. However, 
for the optimized 3 base-pairs, the inter base-pair distance becomes shorter when 
compared to the 2 base-pairs model. For examples, the rise of step A A for A A G is 
4.34 人 and that of the step G G for C G G is 3.64 A, so that better overlapping resulted 
leading to more efficient sharing of electron cloud as observed (Figure 3.2). 
Moreover, although sharing of electron cloud is present, the electron distributes more 
favourably on the 5 ’ side, hence the observed DFT calculation results. Therefore, 
the use of the RHF/ST0-3G method for a qualitative analysis for D N A is ascertain. 
The base-pair steps G G and A G show the greatest shift of around 0.2 人 and 
almost zero slide among basepair steps studied, this could be the reason giving rise 
to the major cisplatin-DNA products, G G and A G intrastrand crosslinks. Because 
the G G step has a smaller rise (4.65 人）and twist (24.29。）compared with the A G 
step (5.03 A and 25.06°), cisplatin-chelation is expected to become more facile 
driven by a better M O overlapping arrangement (Table 3.7). 
Although it is possible to predict that an AG-adduct will form but not GA, 
however the reason remains unclear (3.25). Consider that a larger rise is observed for 
G A step (5.20 A) versus the value of A G step (5.03 人)(Table 3.7)，it would be more 
difficult for ligation of G A to cisplatin. Together with the M O results discussed in 
section 3.6.2，GA-cisplatin is thus structurally and electronically less favourable. 
- 6 6 -
Table 3.8 Inter Base Pair Parameters of Sequence 1G14 
Base-Pair Shift Slide Rise Tilt Roll Twist 
Step (Dx) (Dy) (Dz) (tau) (rho) (Omega) 
G1/G2 -0.74 0.44 2.73 -5.16 2.84 34.00 
G2/C3 -0.07 -0.28 2.85 1.22 -3.04 36.38 
C3/A4 0.44 0.16 2.80 1.49 2.66 35.44 
A4/A5 0.11 -0.04 2.83 -2.37 1.32 34.66 
A5/G6 -0.08 -0.60 3.15 -0.10 -2.07 29.23 
G6/A7 0.46 0.37 3.16 2.46 -0.67 37.26 
A7/A8 -0.03 -0.13 3.21 -2.42 5.10 35.40 
A8/A9 -0.14 0.15 2.82 -0.45 1.28 35.52 
A9/C10 -0.30 0.00 3.18 0.54 -1.28 34.70 
C10/G11 -0.20 -0.03 2.91 -0.80 3.55 33.66 
G11/G12 0.30 -0.25 3.15 -1.97 1.52 31.95 
Average -0.02 -0.02 2.98 -0.69 1.02 34.38 
3.7.2 DNA Sequences from PDB 
The structural features of two D N A sequences with cisplatin binding on G G 
were also analyzed. The sequence is C C T C T G G T C T C from X-Ray (PDB ID 
lAIO) and N M R (1A84) data. Drastic difference is noticed between the X-Ray and 
N M R results (Figure 3.11). 
Segment of T G G T (cisplatin bound on GG) was extracted and compared with 
the optimized T G G T sequence (Figure 3.12). Cisplatin binding gives rise to 
positive shift (1.58 A and 0.27 人）and roll (23.86。and 45.9 and negative slide 
(1.13 A and 0.4 A) resulted from structure compensation. 
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3.7.3 Backbone Torsion Angles 
The orientation of the base of the optimized structures are all anti, that is 
having a pseudorotation angle of (180±90)°, which is the general case for DNA. 
The chi (x) angles of the first and second guanines of the optimized G G G G show 
minimum and maximum values of-134.73° and -100.61。respectively (Appendix I). 
For the sugar ring conformation, the conformation ranges from C3'-endo to C3’-exo 
(Appendix I) as compared with normal DNA, which ranges from Cl'-exo to C3，-exo 
(3.32). The results show that the sugar ring is flexible to facilitate adoption of the 
optimum structure. 
3.8 Summary 
The orbitals and structures of the D N A had been examined theoretically. 
Both the electronic and structural factors heavily influence the ligation of D N A to 
cisplatin. Also, the preference of binding is found to be sequence dependent. A 
set of empirical selection rule has been proposed as means of locating the possible 
sites on D N A for cisplatin-binding. 
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The ligating role of D N A has been theoretically investigated by studying the 
structural and electronic properties of a series of short segment DNAs. The double 
stranded models are 5,-GX-3，，5’-AX-3，，5’-XGG-3’，5，-GGX-3，，5'-GXG-3', 
5'-XAG-3', 5'-AXA-3' and 5'-XGGX-3' (where X = A,T,C and G). Their 
geometries were optimized and an M O analysis of their structures was undertaken. 
To demonstrate the reliability of the utilized method for D N A study, 
comparison had been carried out with the backbone torsion angles and the reference 
distance obtained from experimental data, as well as the location of H O M O 
investigated at higher level of theory. Results were in good agreement with 
experimental values, indicating the employed method, RHF/ST0-3Q was acceptable 
for qualitative purposes. 
Results obtained from ab initio calculation had proven that H O M O is 
localized on G for any G-containing sequence. Thus G is suggested to be regarded 
as the most active site, and is responsible for binding to cisplatin. A set of 
empirical selection rule has been proposed to identify the location of H O M O on 
D N A and hence rationalize the resulting crosslink products formed by binding to 
-72 -
cisplatin binding. The reliability of these rules had been demonstrated with 
experimental data. 
Moreover, chelation of cisplatin is found to be selective and sequence 
dependent, giving specific cisplatin-DNA adducts such as 1,2-d(GpG), 1,2-d(ApG) 
and l，3-d(GpXpG) intrastrand and d(GpC)d(GpC) interstrand crosslinks. The 
preference in the products formation had been discussed from structural and 
electronic points of view. 
The steps formed from A and G bases have been shown to have large rise and 
twist values, as compared to the other two pyrimidine bases. It is believed that the 
rise and twist parameters heavily influence the selectivity of cisplatin-adduct 
formation. Also, the large rise value of the G A step should result in unfavourable 
D N A ligation. 
Extending from this work, longer D N A sequences as models would be 




BACKBONE TORSION ANGLES AND SUGAR RING CONFORMATION OF 
THE OPTIMIZED GEOMETRIES 
Chi Gamma Delta Epsil Zeta Alpha Beta Conformation  




A1 -120.26 I 142.20-157.01 -68.22 -85.27 177.87 C3'-exo 
A2 -114.17 58.57 91.88 I I I I Ol'-endo 
5TT 
T1 -118.98 I 140.02-148.62 -97.51 -52.29 162.06 C2'-endo 
T2 -115.23 55.65 100.57 I I I I Ol'-endo 
(AGJC) 
5'AG 
A1 -116.66 I 140.98 156.41 -68.46 -86.12-177.58 C3'-exo 
G2 -116.62 56.55 97.83 I I I I Ol'-endo 
5'CT 
C1 -119.58 I 138.58-144.84 -97.49 -55.52 166.25 CZ-endo 




G1 -115.81 I 140.92-155.49 -64.96 -91.74-173.81 C3'-exo 
A2 -110.26 55.19 93.10 I I I I Ol'-endo 
5TC 
T1 -117.63 I 134.69-151.06 -102.26 -53.73 168.30 CZ-endo 
C2 -123.20 57.02 92.73 I I I I Ol'-endo 
(GC,GC) 
5'GC 
G1 -119.03 I 141.31 -162.39 -68.94 -84.76 -178.01 C3'-exo 
-74-
(cont'd)  
Chi Gamma Delta Epsil Zeta Alpha Beta Conformation 
Cr-N C5'-C4' C4'-C3' C3'-03' 03'-P P-05' 05'-C5'  
C2 -122.79 57.63 94.75 I I I I Ol'-endo 
5'GC 
G1 -117.83 I 141.43-154.87 -92.32 -56.88 168.81 C3'-exo 
C2 -126.25 54.84 98.80 I I I I Ol'-endo 
(GG’CC) 
5'GG 
G1 -118.64 I 143.33 -147.70 -99.30 -51.72 166.65 C3'-exo 
G2 -122.11 54.44 102.70 t i l l Ol'-endo 
5'CC 
C1 -122.19 I 139.94-152.54-102.17 -52.27 168.86 CZ-endo 
C2 -123.14 25.88 93.51 I I I I Ol'-endo 
(GT,AC) 
5,GT 
G1 -121.01 I 142.08-159.52 -69.38 -84.89-174.62 C3'-exo 
T2 -117.80 56.55 97.80 I I I I Ol'-endo 
5'AC 
A1 -126.55 57.50 100.99 I I I I C3'-exo 




A1 -116.82 I 140.90-155.79 -68.75 -84.40 176.95 C3'-exo 
G2 -116.56 57.97 96.04-175.54 -85.46 -71.70 -174.78 Ol'-endo 
G3 -121.67 58.47 89.71 I I I I C4'-exo 
5'CCT 
C1 -119.88 I 136.97-146.84 -98.93 -53.94 163.34 C2’-endo 
C2 -118.53 56.64 99.64 -156.77 -96.98 -35.56 164.59 Ol'-endo 
T3 -121.45 55.56 100.57 I I I I Ol'-endo 
-75-
(cont'd)  
Chi Gamma Delta Epsil Zeta Alpha Beta Conformation 
Cr-N C5'-C4' C4'-C3' C3'-03' 03'-P P-05' 05'-C5'  
(CGG.GCC) 
5'CGG 
C1 -124.19 I 140.32-156.85 -67.32 -82.96 173.72 CZ-endo 
G2 -122.55 59.93 100.17-171.08 -77.44 -71.39 177.79 Ol'-endo 
G3 -107.10 61.19 89.99 t i l l Ol'-endo 
5'GCC 
C1 -126.02 I 134.50-163.21 -117.53 -54.65 166.80 CZ-endo 
C2 -112.44 56.37 101.74-157.64 -93.92 -52.44 155.60 Ol'-endo 
G3 -111.54 55.75 90.45 I I I I C4'-exo 
(GGG.CCC) 
5'GGG 
G1 -116.91 I 141.05-145.88 -97.54 -52.80 160.24 C3'-exo 
G2 -120.58 55.91 105.33-160.13-101.38 -52.30 169.21 Ol'-endo 
G3 -122.01 54.22 98.81 I I I I Ol'-endo 
5'CCC 
C1 -120.51 I 136.80 -157.84 -72.97 -81.31 -179.56 CZ-endo 
C2 -117.84 60.47 93.47-176.53 -85.09 -67.40 178.93 Ol'-endo 
C3 -124.75 64.46 87.14 I I I I C4’-exo 
(TGG.ACC) 
5TGG 
T1 -121.69 I 103.79 -157.78 -69.04 -82.59 176.86 Ol'-endo 
G2 -117.21 57.44 90.99-178.17 -87.75 -71.35-177.01 Ol'-endo 
G3 -126.69 57.61 91.05 I I I I C3'-endo 
5'ACC 
C1 -119.21 I 137.02-144.18 -99.07 -53.15 160.10 C2_-endo 
C2 -116.49 57.30 100.15-157.43 -95.24 -54.93 161.65 Ol'-endo 




G1 -117.88 I 141.47 -156.24 -69.94 -81.92 179.44 C3'-exo 
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(cont'd)  
Chi Gamma Delta Epsil Zeta Alpha Beta Conformation 
Cr-N C5'-C4' C4'-C3' C3'-03' 03'-P P-05' 05'-C5'  
G2 -117.32 58.88 96.90-176.21 -84.16 -70.22-178.99 Ol'-endo 
A3 -123.97 61.09 88.50 I I I I C4'-exo 
5TCC 
T1 -116.82 I 136.41 -151.02 -95.46 -54.57 163.36 Ol'-endo 
C2 -121.46 56.29 100.14-161.93 -99.97 -52.01 167.70 Ol'-endo 
C3 -124.92 59.51 92.75 I I I I C2'-endo 
(GGC,CCG) 
5'GGC 
G1 -118.86 I 141.65 -150.37 -99.43 -51.55 162.53 C3'-exo 
G2 -121.22 55.65 99.90 -172.05 -76.87 -76.47 179.31 Ol'-endo 
C3 -125.80 58.93 94.33 I I I I Ol'-endo 
5'GCC 
G1 -115.31 I 139.43 -152.66 -87.78 -61.07 167.52 C3_-exo 
C2 -121.70 50.77 98.27-159.40-102.06 -52.53 166.07 Ol'-endo 
C3 -121.58 58.91 93.11 I I I I Ol'-endo 
(GGT’CCA) 
5'GGT 
G1 -119.10 I 140.52-160.90 -74.01 -79.13-178.53 C3'-exo 
G2 -116.93 59.12 96.63-173.37 -81.01 -74.19-176.01 Ol'-endo 
T3 -118.86 58.49 95.55 I I I I Ol'-endo 
5'ACC 
A1 -116.98 I 139.49-151.87 -95.53 -55.04 164.56 C3'-exo 
C2 -121.39 55.87 98.15-158.87 -100.00 -53.09 166.53 Ol'-endo 




G1 -120.74 I 141.11 -156.22 -59.80 -95.28 178.68 C3'-exo 
C2 -114.72 54.56 94.29-166.38 -75.92 -78.38 175.95 Ol'-endo 
G3 -119.48 57.09 96.80 I I I I Ol'-endo 
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(cont'd)  
Chi Gamma Delta Epsil Zeta Alpha Beta Conformation 
Cr-N C5'-C4' C4'-C3' C3'-03' 03'-P P-05' 05'-C5'  
5'CGC 
C1 -118.03 I 137.18-141.13 -92.06 -58.41 157.42 C2'-endo 
G2 -114.92 51.84 104.95-163.44 -90.57 -58.52 168.28 Ol'-endo 
C3 -125.57 53.73 97.29 I I I I Ol'-endo 
(GTG,CAC) 
5'GAG 
G1 -117.87 I 140.90-157.14 -66.56 -86.45-179.68 C3'-exo 
T2 -115.14 57.86 97.24-161.32 -97.39 -51.80 160.57 Ol'-endo 
G3 -123.62 55.25 98.31 I I I I Ol'-endo 
5'CAC 
C1 -118.82 I 135.71 -141.34 -98.69 -54.55 155.24 C2'-endo 
A2 -110.52 55.03 102.09-163.94 -96.54 -53.71 166.61 Ol'-endo 




A1 -116.02 I 129.37-145.22-147.84 -64.42 166.49 Cl'-exo 
A2 -106.37 55.00 136.33 -166.11 -74.70 -79.18-177.58 C2'-endo 
G3 -121.48 57.80 98.65 t i l l Ol'-endo 
5TTC 
C1 -121.16 I 137.74-148.23 -97.56 -54.82 165.63 C2’-endo 
T2 -119.32 55.37 104.43-158.45 -94.32 -51.70 160.8 Ol'-endo 
T3 -120.22 57.14 97.64 I I I I Ol'-endo 
(CAG,GTC) 
5'CAG 
C1 -119.98 I 138.6 -150.56 -63.77 -91.90 175.03 C2_-endo 
A2 -103.49 57.43 97.45-161.69 -98.15 -51.51 159.65 Ol'-endo 
G3 -123.78 56.05 97.82 I I I I Ol'-endo 
5'GTC 
C1 -118.27 I 135.68-142.02 -96.78 -54.77 158.15 C2_-endo 
T2 -115.78 54.95 101.09-156.47 -94.78 -55.34 162.22 Ol'-endo 
-78-
(cont'd)  
Chi Gamma Delta Epsil Zeta Alpha Beta Conformation 
Cr-N C5'-C4' C4'-C3' C3'-03' 03'-P P-05' 05'-C5'  
G3 -119.91 52.76 102.48 I I I I Ol'-endo 
(GAG.CTC) 
5'GAG 
G1 -119.04 I 140.26 -161.85 -72.59 -81.10-179.53 C3'-exo 
A2 -115.15 58.88 98.11 -162.01 -100.15 -50.91 162.46 Ol'-endo 
G3 -124.58 55.99 96.42 I I I I Ol'-endo 
5'CTC 
C1 -119.21 I 135.88-142.98 -99.53 -52.85 156.42 C2'-endo 
T2 -114.23 56.87 98.51 -162.21 -95.76 -54.15 165.74 Ol'-endo 
C3 -124.00 57.56 94.91 I I I I Ol'-endo 
(TAG，ATC) 
STAG 
T1 -119.31 I 138.78 -155.14 -65.19 -88.83 177.51 CZ-endo 
A2 -109.79 56.62 97.77-168.64 -77.49 -76.84 179.01 Ol'-endo 
G3 -120.99 57.67 96.34 I I I I Ol'-endo 
5'CTC 
C1 -121.90 I 102.13-152.93 -97.08 -53.22 162.40 Ol'-endo 
T2 -118.89 57.30 101.70-159.45 -95.90 -54.09 164.41 Ol'-endo 




A1 -116.90 I 140.98 -157.97 -69.44 -84.45 179.09 C3'-exo 
A2 -112.88 57.50 96.01 -169.63 -78.76 -76.14 178.60 Ol'-endo 
A3 -120.20 59.29 92.53 I I I I Ol'-endo 
5TTT 
T1 -122.60 I 103.94-157.92 -96.28 -53.15 164.92 Ol'-endo 
T2 -121.30 57.05 101.48 -159.33 -97.02 -53.16 167.15 Ol'-endo 
T3 -122.81 55.40 101.32 I I I I Ol'-endo 
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(cont'd)  
Chi Gamma Delta Epsil Zeta Alpha Beta Conformation 
Cr-N C5'-C4' C4'-C3' C3'-03' 03'-P P-05' 05'-C5'  
(AGAJCT) 
5'AGA 
A1 -115.90 / 140.59-156.09 -70.82 -80.90 174.46 C3'-exo 
G2 -111.57 59.33 94.87-174.41 -82.93 -71.25 -179.67 Ol'-endo 
A3 -124.19 60.88 87.84 I I I I C4'-exo 
5TCT 
T1 -117.06 I 137.58-151.61 -95.18 -54.58 164.08 C2'-endo 
C2 -121.47 56.14 101.01 -156.65 -95.52 -54.60 166.05 Ol'-endo 




A1 -119.38 I 102.74-162.88 -77.69 -76.35 179.38 Ol'-endo 
G2 -118.72 59.47 98.86-169.29 -82.46 -70.03 179.93 Ol'-endo 
G3 -119.69 62.26 94.26-172.10 -80.90 -73.01 179.57 Ol'-endo 
A4 -124.69 60.57 87.70 I I I I C4'-exo 
5TCCT 
T1 -118.36 I 101.54-156.38 -96.38 -53.53 164.88 Ol'-endo 
C2 -120.29 56.76 99.79-156.17 -98.17 -52.78 164.35 Ol'-endo 
C3 -119.53 58.18 99.49-155.03 -95.79 -53.84 163.80 Ol'-endo 
T4 -121.66 55.64 100.70 I I I I Ol'-endo 
(CGGC.GCCG) 
5'CGGC 
C1 -120.74 I 139.98-149.47 -57.13 -97.53 173.92 CZ-endo 
G2 -106.08 56.21 96.69 -172.55 -81.22 -70.18 176.10 Ol'-endo 
G3 -119.81 61.10 97.19-164.00 -92.47 -54.75 165.32 Ol'-endo 
C4 -127.44 56.64 96.94 I I I I Ol'-endo 
5'GCCG 
G1 -116.33 I 99.83 -157.07 -90.61 -58.88 167.69 Ol'-endo 
C2 -119.86 52.57 98.68 -154.57 -98.96 -53.56 164.20 Ol'-endo 
C3 -114.28 57.12 100.18-151.02 -92.64 -57.40 161.32 Ol'-endo 
- 8 0 -
(cont'd)  
Chi Gamma Delta Epsil Zeta Alpha Beta Conformation 
Cr-N C5'-C4' C4'-C3' C3'-03' 03'-P P-05' 05'-C5'  
G4 -116.45 52.12 104.66 I I I I Ol'-endo 
(GGGG.CCCC) 
5'GGGG 
G1 -134.73 I 141.02-160.86 -68.94 -77.93 178.23 C2'-endo 
G2 -100.61 62.95 90.14-165.05 -78.94 -75.58 173.29 Ol'-endo 
G3 -114.74 61.20 92.48-177.59 -82.87 -72.05 179.78 Ol'-endo 
G4 -125.67 58.17 91.21 I I I I C3'-endo 
5'CCCC 
C1 -118.56 I 135.82-139.42-103.32 -50.65 152.68 C3'-exo 
C2 -111.40 58.99 98.90-160.54-103.61 -45.38 152.41 OV-endo 
C3 -128.88 66.05 97.58-170.55-100.03 -51.83 170.17 Ol'-endo 
C4 -120.38 60.40 89.15 I I I I Ol'-endo 
(TGGT,ACCA) 
5TGGT 
T1 -120.17 I 139.23-153.99 -62.72 -91.55 177.71 C2'-endo 
G2 -112.13 56.35 98.33-161.18-100.85 -50.13 160.64 Ol'-endo 
G3 -120.63 58.88 98.60-161.77-100.95 -50.84 168.24 Ol'-endo 
T4 -121.10 56.36 97.51 I I I I Ol'-endo 
5'ACCA 
A1 -116.18 I 140.29-151.54 -98.16 -54.18 166.74 C3'-exo 
C2 -118.88 55.97 97.68-155.13-100.34 -51.41 161.23 Ol'-endo 
C3 -116.57 59.72 98.94-157.47 -96.61 -53.82 161.94 Ol'-endo  
A4 -122.75 57.03 95.84 I I I I Ol'-endo 
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APPENDIX II 
BACKBONE TORSION ANGLES OF THE EXPERIMENTAL SEQUENCES 
FROM NUCLEIC ACID DATABASE (NDB) 
(a) 5,-G ⑴ 
a P Y S e C X  
Average value 
overall -109.40 183.32 116.26 135.10 196.49 -114.87 -117.33 
(250.60) (183.32) (116.26) (135.10) (196.49) (245.13) (242.67) 
NMR -69.36 172.04 65.62 129.91 172.21 -102.78 -110.69 
(290.64) (172.04) (65.62) (129.91) (172.21) (257.22) (249.31) 
X-Ray -114.98 184.81 123.42 135.83 199.92 -116.58 -118.26 
(245.02) (184.81) (123.42) (135.83) (199.92) (243.42) (241.74) 
Average value with terminated GGG only 
overall n.a. n.a. 238.28 138.38 187.01 -103.81 -118.61 
n.a. n.a. (238.28) (138.38) (187.01) (256.19) (241.39) 
NMR n.a. n.a. 88.05 127.25 143.82 -65.50 -116.02 
n.a. n.a. (88.05) (127.25) (143.82) (294.50) (243.98) 
X-Ray n.a. n.a. 239.82 124.67 195.26 -108.30 -120.78 
n.a. n.a. (239.82) (124.67) (195.26) (251.70) (239.22) 
Average value with GGGG sequence 
overall -149.57 192.18 170.53 134.56 192.41 -106.92 -121.35 
(210.43) (192.18) (170.53) (134.56) (192.41) (253.08) (238.65) 
NMR -57.06 161.13 64.10 136.80 184.65 -103.54 -124.12 
(302.94) (161.13) (64.10) (136.80) (184.65) (256.46) (235.88) 
X-Ray -158.52 195.19 178.51 134.39 192.99 -107.18 -121.14 
(201.48) (195.19) (178.51) (134.39) (192.99) (252.83) (238.86) 
Standard deviation 
overall 94.82 34.91 102.86 19.60 35.83 46.91 34.78 
NMR 16.39 15.85 34.07 14.42 25.34 33.61 20.35 
X-Ray 99.84 36.50 107.03 20.26 35.73 48.38 36.34 
- 8 2 -
(cont'd)  
a p I 5 s C X  
Standard deviation with terminated GGG only 
overall n.a. n.a. 107.48 14.61 33.65 38.45 21.43 
NMR n.a. n.a. 80.56 19.68 49.30 37.44 28.15 
X-Ray n.a. n.a. 87.39 13.23 24.33 35.20 21.07 
Standard deviation with GGGG sequence 
overall 120.74 43.50 123.31 24.06 33.25 46.35 23.22 
NMR 3.70 3.10 1.58 13.46 5.40 15.87 4.79 
X-Ray 122.87 44.45 124.25 24.78 34.41 47.95 24.06 
NMR 
169D n.a. n.a. 180.63 108.04 178.35 -87.69 -130.51 
1G5K -65.86 192.16 64.59 143.60 173.80 -100.21 -122.14 
1GJ1 -73.96 182.02 55.03 132.60 183.63 -118.70 -103.11 
1IV6 -57.20 165.31 60.18 141.76 185.09 -97.26 -128.20 
-79.09 174.49 53.80 111.01 183.18 -96.98 -118.04 
1J5N -45.71 143.08 56.09 113.65 169.24 -97.84 -111.86 
n.a. n.a. 49.62 126.36 87.36 -22.26 -83.58 
1KBD -59.46 159.36 62.38 143.94 189.97 -109.98 -124.00 
1KVH -83.33 198.38 60.88 110.99 170.85 -98.63 -89.47 
1LFU n.a. n.a. 33.90 147.36 165.76 -86.54 -133.98 
1LWA -52.80 164.72 64.45 121.28 179.19 -85.46 -128.97 
1N0K -96.75 175.74 56.58 135.75 179.17 -165.65 -75.47 
1NOO -89.92 177.83 55.05 137.20 180.53 -156.49 -80.94 
2KBD -58.90 159.32 65.47 145.19 184.78 -115.19 -119.40 
X-Ray 
PD0005 -59.21 238.19 27.59 150.67 181.60 -129.13 -95.31 
-233.71 162.85 176.82 147.11 196.57 -113.11 -140.19 
PD0010 -58.18 167.90 55.93 147.17 212.40 -138.27 -92.16 
n.a. 197.13 59.67 144.09 199.05 -145.72 -85.85 
PD0023 -119.81 213.69 71.95 108.57 153.60 -71.94 -117.33 
-159.89 244.85 105.47 91.18 168.11 -77.85 -120.92 
PD0024 n.a. n.a. 194.55 147.14 240.69 -171.67 -97.31 
n.a. n.a. 187.86 146.19 240.63 -175.56 -97.95 
-83-
(cont'd)  
a P Y 5 e C X  
PD0030 n.a. n.a. 293.41 147.13 162.08 -149.03 -156.29 
PD0032 -98.54 140.08 184.20 85.10 215.95 -81.57 -179.57 
PD0033 n.a. n.a. 3.79 152.19 163.01 -148.11 -165.20 
PD0041 -90.26 179.66 58.81 147.81 209.76 -152.63 -58.40 
PD0068 -163.05 229.09 63.44 149.38 222.40 -126.08 -106.06 
PD0095 -279.17 190.08 181.67 147.04 189.12 -119.38 -118.60 
-271.38 193.84 176.70 146.40 189.25 -121.33 -121.38 
PD0105 -329.64 209.08 279.95 153.36 170.98 -89.64 -124.66 
PD0112 n.a. n.a. 326.77 148.48 184.81 -88.14 -125.20 
-2.87 267.42 264.78 154.76 186.60 -74.50 -133.15 
n.a. n.a. 338.76 148.67 182.98 -93.06 -123.28 
-349.02 268.51 271.14 149.82 184.64 -80.08 -135.72 
n.a. n.a. 333.61 145.57 186.79 -90.59 -126.29 
-71.39 192.66 36.63 137.85 185.83 -101.37 -109.85 
n.a. n.a. 332.10 147.48 188.58 -92.91 -121.84 
-355.43 262.67 269.96 150.18 183.09 -76.50 -130.67 
n.a. n.a. 333.67 145.65 185.08 -88.57 -124.44 
-348.03 257.87 274.41 148.74 183.72 -78.08 -134.01 
PD0145 -21.05 180.83 359.81 160.08 194.30 -110.39 -105.54 
-289.55 107.86 325.64 152.89 174.72 -127.30 -71.63 
PD0146 -348.31 195.24 305.43 165.31 189.93 -93.39 -111.10 
-334.21 189.44 303.02 160.56 156.30 -72.81 -106.05 
PD0155 -62.86 179.63 51.52 139.75 202.80 -137.78 -290.63 
-67.78 175.36 60.32 134.27 205.52 -127.00 -298.32 
PD0165 -50.19 148.03 45.44 125.26 189.06 -113.96 -130.11 
-57.05 141.48 38.97 118.09 191.90 -113.74 -133.31 
-57.67 134.92 39.57 119.17 192.73 -115.13 -132.76 
-59.78 140.68 50.41 124.65 191.45 -117.16 -134.53 
-71.19 178.05 50.42 143.57 194.06 -151.05 -102.96 
-43.32 142.28 38.10 130.65 182.26 -106.93 -127.33 
PD0192 -42.76 169.90 50.93 146.42 209.31 -102.08 -96.92 
PD0200 -60.16 175.44 34.79 153.57 237.41 -178.97 -65.51 
PD0219 -69.63 174.23 33.05 142.83 226.71 -145.18 -90.27 
-74.25 176.40 35.99 143.23 243.41 -172.24 -90.89 
-76.99 176.62 38.92 142.25 243.22 -170.68 -91.91 
-84-
(cont'd)  
a p Y 5 E C X  
-72.47 175.66 35.58 141.27 226.02 -144.69 -91.01 
PD0221 -205.05 218.81 164.15 136.69 244.87 -163.59 -112.24 
PD0222 n.a. n.a. 298.95 150.49 236.57 -76.71 -81.76 
PD0230 -43.14 142.11 41.06 133.80 181.37 -104.09 -127.16 
PD0231 -46.01 141.56 44.34 133.48 181.78 -102.92 -123.08 
PD0251 -59.86 151.23 36.17 145.60 195.28 -94.67 -115.89 
PD0252 -262.97 216.93 190.27 143.56 208.24 -74.46 -143.89 
PD0259 -78.46 174.03 44.85 150.85 309.17 107.94 -78.00 
-56.49 163.15 48.83 139.85 193.71 -139.56 -95.70 
PD0270 -282.06 226.18 179.06 101.39 221.64 -96.27 -171.48 
PD0286 -51.70 179.30 41.37 136.15 272.40 -211.83 -84.49 
-64.37 201.33 29.31 139.27 235.00 -167.25 -89.56 
-56.03 174.06 50.12 138.74 170.62 -121.66 -106.23 
-29.78 179.73 52.36 142.56 181.53 -103.89 -101.74 
PD0307 -209.67 190.89 179.60 137.91 224.96 -83.84 -154.07 
61.94 204.88 172.70 89.81 170.72 -48.88 -139.50 
PD0309 -96.61 214.70 50.03 137.46 136.39 -75.84 -79.96 
-76.35 154.43 56.40 145.03 204.24 -104.30 -78.57 
PD0310 -69.93 183.56 30.65 139.32 284.16 -201.38 -98.71 
PD0312 -51.21 142.90 42.02 130.47 182.42 -106.37 -133.92 
-50.57 143.22 47.97 137.52 177.10 -99.41 -116.38 
PD0316 -67.08 170.57 53.70 147.63 239.81 -190.08 -116.61 
-230.77 150.61 170.79 146.49 184.32 -106.24 -135.85 
PD0319 -62.42 191.26 48.06 148.66 170.84 -124.58 -76.03 
PD0320 -49.71 187.77 38.62 145.82 151.30 -101.30 -84.67 
PD0338 -92.99 192.35 55.73 161.69 319.34 -236.91 -77.07 
PD0364 -54.53 184.63 43.16 142.35 182.98 -135.16 -93.02 
PD0365 -59.16 184.13 47.88 142.80 193.79 -137.48 -88.97 
PD0393 n.a. n.a. 333.27 108.44 175.84 -55.59 -133.48 
-103.60 174.13 84.89 109.08 196.13 -96.70 -125.26 
-62.53 178.98 43.68 117.68 58.26 -308.11 -98.70 
-167.94 206.79 60.20 151.50 314.87 -217.40 -84.67 
-81.88 147.64 13.14 123.72 156.71 -90.34 -100.82 
PD0424 -58.75 147.27 39.98 141.38 204.99 -115.61 -131.97 
-72.70 124.38 54.34 106.79 190.80 -124.55 -141.06 
-85-
(cont'd)  
a p Y 5 E C X  
PD0429 -8.69 293.87 255.56 145.77 171.86 -85.70 -121.14 
-76.30 208.90 48.20 140.95 163.33 -86.02 -92.97 
-295.22 266.90 201.65 141.49 226.65 -153.99 -124.21 
-42.11 138.18 45.46 137.73 179.17 -126.59 -106.63 
PD0504 n.a. n.a. 289.55 136.23 191.56 -96.56 -106.42 
-52.70 172.01 35.42 139.54 225.51 -178.82 -94.27 
-50.27 141.45 43.44 138.87 191.73 -93.26 -113.56 
PD0505 n.a. n.a. 281.74 127.08 200.77 -98.29 -113.26 
-56.19 163.35 45.42 140.02 231.74 -177.30 -94.09 
n.a. n.a. 280.16 135.92 194.23 -91.44 -118.25 
-64.54 172.88 46.97 143.12 231.25 -171.17 -100.40 
PDE003 n.a. n.a. 220.27 113.25 192.07 -122.19 -109.36 
n.a. n.a. 214.75 147.53 196.01 -137.40 -105.12 
PDE011 n.a. 220.21 105.61 125.36 195.88 -84.19 -119.98 
PDE012 n.a. 214.59 69.57 145.30 219.99 -107.85 -110.70 
n.a. 244.04 37.48 163.60 171.43 -89.94 -92.06 
PDE0128 -145.06 189.81 73.06 82.01 207.23 -70.05 -172.87 
-79.51 181.57 49.90 90.56 210.60 -66.96 -162.61 
-78.19 169.78 57.67 73.49 196.67 -64.32 -172.92 
-92.86 182.51 71.48 76.53 219.43 -93.26 -176.20 
-300.37 158.36 55.71 67.74 204.36 -61.52 -168.17 
(b) 5'-G(2) 
a P Y S s C X  
Average value 
overall -90.62 -177.62 68.37 130.53 191.46 -106.80 -116.98 
(269.38) (182.38) (68.37) (130.53) (191.46) (253.20) (243.02) 
NMR -90.09 -166.41 76.60 133.50 185.17 -107.94 -118.12 
(269.91) (193.59) (76.60) (133.50) (185.17) (252.06) (241.88) 
- 8 6 -
(cont'd)  
a P Y § s C X  
X-Ray -90.68 -179.09 67.29 130.14 192.29 -106.66 -116.83 
(269.32) (180.91) (67.29) (130.14) (192.29) (253.34) (243.17) 
Average value with terminated GGG only 
overall -68.00 -191.93 51.30 128.49 195.60 -106.31 -116.01 
(292.00) (168.07) (51.30) (128.49) (195.60) (253.69) (243.99) 
NMR -80.45 -172.24 57.71 130.46 179.64 -104.55 -118.55 
(279.55) (187.76) (57.71) (130.46) (179.64) (255.45) (241.45) 
X-Ray -73.18 -192.63 53.72 127.75 201.77 -108.10 -118.02 
(286.83) (167.37) (53.72) (127.75) (201.77) (251.90) (241.98) 
Average value with GGGG sequence 
overall -79.92 -174.03 53.06 128.78 194.66 -108.78 -117.43 
(280.08) (185.97) (53.06) (128.78) (194.66) (251.22) (242.57) 
NMR -74.92 -175.51 61.26 135.55 182.47 -104.93 -121.16 
(285.08) (184.49) (61.26) (135.55) (182.47) (255.07) (238.84) 
X-Ray -80.29 -173.92 52.45 128.27 195.57 -109.06 -117.14 
(279.71) (186.08) (52.45) (128.27) (195.57) (250.94) (242.86) 
Standard deviation 
overall 71.54 56.86 61.21 22.89 31.45 43.09 26.20 
NMR 61.08 31.36 44.12 9.90 16.84 18.90 13.44 
X-Ray 73.08 59.35 63.21 24.08 32.86 45.38 27.49 
Standard deviation with terminated GGG only 
overall 25.29 31.29 27.19 18.35 20.92 35.35 17.90 
NMR 20.78 16.65 2.70 9.92 7.21 13.50 8.93 
X-Ray 25.94 32.34 29.60 19.75 21.40 38.40 19.29 
Standard deviation with GGGG sequence 
overall 48.33 59.41 47.21 22.90 44.55 56.91 30.93 
NMR 25.43 20.18 6.82 11.96 8.80 13.80 11.56 
X-Ray 49.80 61.48 48.91 23.53 46.06 58.96 32.00 
-87-
(cont'd)  
a P Y S e g X  
NMR 
169D -73.01 -182.22 57.83 128.27 179.81 -111.45 -122.86 
1G5K -80.26 -162.15 57.93 142.10 187.14 -105.28 -124.73 
1GJ1 -60.54 -186.84 66.36 138.31 167.14 -92.50 -93.81 
1IV6 -67.39 -185.30 59.04 129.96 182.79 -109.75 -124.14 
-65.30 -193.63 61.39 118.43 180.81 -93.71 -126.49 
1J5N -24.38 -182.88 28.10 120.98 173.20 -90.06 -112.02 
1KBD -64.41 -181.49 54.95 141.29 186.75 -113.22 -124.51 
1KVH -67.27 -177.39 61.89 123.91 190.91 -86.43 -97.96 
1LFU -64.78 -162.64 73.51 146.72 162.26 -111.50 -103.67 
1LWA -103.93 -153.02 60.34 121.81 172.35 -88.99 -108.29 
1N0K -233.07 -112.18 178.42 141.51 218.93 -148.13 -132.33 
1NOO -210.38 -91.52 167.52 138.64 216.85 -139.62 -134.04 
2KBD -56.43 -192.02 68.49 143.56 188.30 -112.56 -130.68 
X-Ray 
PD0005 -252.28 -118.45 174.09 152.00 182.40 -54.16 -155.37 
-326.08 -232.57 318.49 151.32 215.00 -137.26 -108.36 
PD0010 -54.49 -218.33 53.45 116.66 180.49 -88.92 -114.99 
-36.60 -218.04 47.78 137.60 196.10 -118.11 -106.29 
PD0023 -103.92 -161.16 75.61 111.30 185.71 -75.29 -128.80 
-77.07 175.15 67.20 92.76 163.13 -37.78 -137.99 
PD0024 -72.75 -210.92 46.49 139.87 183.03 -96.46 -116.03 
-75.18 -207.90 45.26 140.84 190.02 -101.16 -117.31 
PD0030 -84.30 -185.68 55.67 84.21 196.57 -57.84 -159.22 
PD0032 -75.04 -186.62 60.80 85.85 196.76 -57.05 -162.29 
PD0033 -76.67 -191.82 50.37 82.22 187.34 -43.50 -156.52 
PD0041 -60.21 -223.94 62.17 149.08 181.72 -121.94 -98.77 
PD0068 -61.16 162.62 29.99 145.04 272.59 85.87 -244.42 
PD0095 -51.30 -170.80 42.19 135.22 273.42 -157.47 -94.42 
-58.15 -168.84 43.54 130.43 271.49 -159.16 -93.47 
PD0105 -68.90 -145.06 40.00 154.15 182.73 -116.08 -99.20 
PD0112 -73.79 -165.79 42.20 130.86 188.16 -92.88 -114.06 
-81.72 -166.10 43.70 137.11 191.87 -109.70 -111.60 
-62.16 -168.48 35.67 132.85 185.07 -94.57 -111.70 
-88-
(cont'd)  
a p Y 5 E C X  
-85.07 -156.28 44.03 139.57 184.18 -102.26 -104.99 
-63.92 -170.10 38.29 130.61 191.63 -94.42 -116.04 
-71.39 -167.34 36.63 137.85 185.83 -101.37 -109.85 
-60.91 -174.20 36.27 130.34 185.76 -92.04 -111.71 
-80.83 -159.41 41.82 135.83 182.23 -99.06 -106.79 
-68.41 -167.86 41.00 134.38 190.37 -98.39 -113.15 
-82.70 -159.71 44.53 141.69 189.57 -108.02 -109.75 
PD0145 -45.45 -158.16 -1.11 139.20 113.44 -57.36 -102.32 
-209.42 -307.94 133.59 176.93 251.65 -108.64 
PD0146 -35.11 -153.06 -16.71 138.48 119.95 -56.75 -107.42 
-104.48 -146.37 53.18 101.02 114.59 -57.80 -113.99 
PD0155 -63.05 -195.87 56.39 143.72 179.64 -93.65 -107.78 
-67.69 -190.98 55.68 147.72 182.06 -100.63 -101.84 
PD0165 -60.28 -176.04 54.29 142.58 178.36 -85.21 -105.01 
-54.86 -191.77 60.12 143.72 197.50 -114.37 -117.92 
-51.78 -185.05 52.73 142.53 183.57 -89.60 -108.34 
-59.51 -188.76 60.28 139.64 176.56 -81.53 -123.21 
-53.49 -210.91 62.92 140.85 182.48 -86.41 -130.13 
-61.79 -162.33 48.66 142.38 172.04 -83.48 -107.12 
PD0192 -55.05 -202.57 36.43 142.11 252.27 -203.46 -75.80 
PD0200 -67.26 -222.07 49.35 147.54 210.76 -150.80 -89.90 
PD0219 -85.69 -228.59 63.74 70.74 189.90 -69.03 -160.44 
-307.19 -134.07 202.46 85.29 213.82 -66.69 -169.92 
-307.39 -132.27 203.94 85.32 214.06 -65.68 -168.69 
-82.20 -229.00 61.26 71.69 185.43 -65.82 -161.92 
PD0221 -44.60 -227.42 31.66 136.01 171.11 -106.62 -92.35 
PD0222 -109.33 -296.39 148.21 150.57 242.20 -118.16 -122.57 
PD0230 -58.62 -172.54 49.76 144.23 198.03 -123.48 -120.73 
PD0231 -58.53 -171.07 45.54 141.59 175.62 -95.56 -115.22 
PD0251 -74.61 -189.36 52.63 135.95 195.79 -135.47 -103.68 
PD0252 -72.72 -187.24 45.04 140.14 210.22 -149.12 -97.96 
PD0259 -180.32 -140.64 75.60 131.03 195.80 -122.88 -112.59 
-41.38 -200.70 35.87 134.98 202.42 -120.16 -113.60 
PD0270 -29.21 -197.90 44.06 135.11 187.45 -95.12 -131.05 
PD0286 -77.05 -218.11 44.35 145.00 182.59 -115.77 -97.17 
-89-
(cont'd)  
a P Y S 8 C X  
-49.60 -230.05 42.05 140.85 180.29 -143.83 -97.87 
-55.52 -178.91 49.64 145.30 193.82 -158.78 -84.25 
-42.39 -181.46 47.88 142.21 177.26 -78.03 -115.06 
PD0307 -68.48 -196.88 37.84 140.71 250.38 -190.95 -88.57 
-86.05 -171.24 52.15 80.46 144.98 -86.68 -134.41 
PD0309 -56.02 -141.61 39.09 148.61 200.84 -181.24 -95.29 
-89.33 -197.77 56.81 141.38 185.04 -140.46 -80.93 
PD0310 -297.32 -133.72 196.00 141.33 219.41 -135.50 -131.15 
PD0312 -46.85 -176.07 39.60 140.74 181.58 -106.36 -122.53 
-72.63 -164.43 52.42 141.39 199.44 -104.88 -106.71 
PD0316 -264.06 -105.71 177.90 135.65 207.48 -88.60 -151.97 
-316.93 -220.40 312.08 147.67 180.72 -113.40 -105.18 
PD0319 -52.79 -185.01 56.44 149.79 162.29 -93.04 -99.58 
PD0320 -46.11 -164.63 52.29 155.89 190.51 -128.36 -90.46 
PD0338 -149.91 -165.56 57.01 143.88 203.85 -121.76 -103.35 
PD0364 -41.66 -193.31 40.91 144.14 188.94 -138.57 -104.52 
PD0365 -41.02 -198.22 39.29 141.88 179.72 -145.38 -90.29 
PD0393 -103.60 -185.87 84.89 109.08 196.13 -96.70 -125.26 
-62.53 -181.02 43.68 117.68 58.26 -308.11 -98.70 
-167.94 -153.21 60.20 151.50 314.87 -217.40 -84.67 
-81.88 -212.36 13.14 123.72 156.71 -90.34 -100.82 
-84.44 -164.96 65.94 107.13 160.95 -56.78 -123.53 
PD0424 -55.91 -186.04 41.91 140.44 190.81 -116.46 -130.09 
-318.41 -192.66 315.33 170.93 187.40 -100.84 -124.34 
PD0429 -76.30 -151.10 48.20 140.95 163.33 -86.02 -92.97 
-49.57 -167.74 40.44 137.75 189.12 -118.21 -100.50 
-42.11 -221.82 45.46 137.73 179.17 -126.59 -106.63 
-319.53 -209.10 321.03 151.35 189.73 -77.35 -91.35 
PD0504 -52.70 -187.99 35.42 139.54 225.51 -178.82 -94.27 
-62.05 -179.90 36.44 140.66 199.53 -139.78 -93.56 
-40.42 -211.16 38.00 138.35 206.92 -164.87 -107.15 
PD0505 -56.19 -196.65 45.42 140.02 231.74 -177.30 -94.09 
-55.67 -214.24 39.85 137.59 199.79 -98.62 -113.07 
-64.54 -187.12 46.97 143.12 231.25 -171.17 -100.40 
-67.68 -211.86 49.62 139.65 186.90 -91.02 -117.14 
-90-
PDE003 -23.87 -201.98 21.80 136.18 181.93 -100.91 -92.64 
-2.24 -231.14 27.60 125.24 170.80 -91.91 -103.53 
PDE011 -84.99 -184.10 51.23 119.27 164.51 -94.36 -101.99 
PDE012 -69.61 -229.23 79.04 75.49 195.32 -74.14 -153.71 
-94.64 -142.32 37.16 141.64 161.94 -102.30 -78.09 
PDE0128 -79.51 -178.43 49.90 90.56 210.60 -66.96 -162.61 
-78.19 -190.22 57.67 73.49 196.67 -64.32 -172.92 
-92.86 -177.49 71.48 76.53 219.43 -93.26 -176.20 
-59.63 -201.64 55.71 67.74 204.36 -61.52 -168.17 
-70.99 -198.60 61.98 73.15 204.04 -88.80 -177.18 
(c) 5'-G(3) 
a P Y S e C X  
Average value 
overall -85.98 -185.20 62.97 129.59 191.31 -113.09 -116.29 
(274.02) (174.80) (62.97) (129.59) (191.31) (246.91) (243.71) 
NMR -74.42 -187.14 58.03 130.12 162.66 -125.86 -118.40 
(285.58) (172.86) (58.03) (130.12) (162.66) (234.14) (241.60) 
X-Ray -87.50 -184.94 63.62 129.52 193.50 -112.11 -116.01 
(272.50) (175.06) (63.62) (129.52) (193.50) (247.89) (243.99) 
Average value with GGGG sequence 
overall -87.60 -185.87 64.25 126.73 191.55 -111.98 -117.34 
(272.40) (174.13) (64.25) (126.73) (191.55) (248.02) (242.66) 
NMR -64.45 -175.11 56.94 133.05 173.55 -104.42 -121.37 
(295.55) (184.89) (56.94) (133.05) (173.55) (255.58) (238.63) 
X-Ray -89.34 -186.68 64.79 126.25 193.10 -112.63 -117.04 
(270.66) (173.32) (64.79) (126.25) (193.10) (247.37) (242.96) 
Standard deviation 
overall 65.85 28.03 52.65 21.74 36.35 52.25 22.01 
NMR 11.52 36.77 8.11 16.80 79.97 64.09 14.65 
X-Ray 69.82 26.90 55.93 22.37 30.55 51.53 22.84 
-91 -
(cont'd)  
a P Y S 8 C X  
Standard deviation with GGGG sequence 
overall 61.92 29.33 52.45 21.92 34.79 68.88 24.61 
NMR 0.69 3.33 5.67 18.08 22.60 8.85 4.10 
X-Ray 63.91 30.27 54.37 22.30 35.44 71.78 25.50 
NMR 
169D -78.07 -176.59 63.55 130.69 179.76 -86.67 -129.76 
1G5K -82.85 -174.78 48.25 87.03 n.a. n.a. -134.06 
1GJ1 -72.17 -162.88 48.56 147.26 n.a. n.a. -95.84 
1IV6 -66.57 -271.83 59.20 134.39 288.91 -101.98 -122.00 
-67.29 -240.70 57.84 130.30 n.a. n.a. -123.47 
1J5N -82.37 -164.36 46.16 130.96 23.32 -269.85 -100.82 
1KBD -63.72 -173.40 52.36 142.47 187.18 -108.98 -118.80 
1KVH -105.07 -134.44 57.43 115.27 n.a. n.a. -97.23 
1LFU -80.71 -163.04 70.94 146.50 126.00 -109.29 -103.68 
1LWA -65.08 -178.95 63.29 112.21 147.46 -94.22 -126.10 
1N0K -68.88 -208.61 59.68 134.04 n.a. n.a. -142.02 
1NOO -70.14 -210.31 71.94 135.98 n.a. n.a. -126.22 
2KBD -64.55 -172.99 55.19 144.49 186.00 -110.06 -119.22 
X-Ray 
PD0005 -224.31 -223.48 178.83 149.72 164.91 -110.82 -116.41 
-93.62 -208.68 63.08 107.37 195.86 -106.46 -159.41 
PD0010 -51.81 -186.86 48.37 144.21 255.55 -171.38 -98.56 
-41.94 -203.85 43.09 141.53 261.24 -176.02 -99.06 
PD0023 -89.32 -186.28 61.04 101.98 154.29 -95.01 -133.61 
-115.32 -158.12 49.94 87.61 137.58 -78.02 -128.57 
PD0024 -63.50 -170.65 38.33 139.60 183.97 -117.25 -104.18 
-60.88 -176.40 40.76 133.61 185.82 -104.61 -108.17 
PD0030 -76.37 -168.02 49.43 81.91 187.94 -75.36 -145.11 
PD0032 -75.64 -168.43 49.78 80.16 188.71 -72.95 -148.43 
PD0033 -85.33 -162.23 49.71 79.59 183.01 -71.48 -145.44 
PD0041 -59.21 -193.36 61.75 138.18 232.85 -52.02 -117.99 
PD0068 -82.52 -192.10 56.72 130.70 229.62 -81.57 -92.56 
PD0095 -40.91 -214.85 48.68 138.86 170.95 -86.19 -94.29 
-92-
(cont'd)  
a P Y S 8 C X  
-59.56 -198.45 53.22 141.96 170.25 -82.05 -94.74 
PD0105 37.66 -158.31 295.62 153.95 174.01 -84.25 -122.29 
PD0112 -68.09 -181.09 48.18 140.41 204.01 -174.24 -102.57 
-50.09 -202.29 51.05 113.72 n.a. n.a. -136.51 
-57.59 -181.71 40.14 143.70 203.21 -167.57 -99.05 
-57.54 -191.71 48.54 120.08 n.a. n.a. -127.11 
-63.32 -185.39 44.17 142.86 207.04 -176.49 -101.43 
-57.47 -189.01 50.91 117.13 n.a. n.a. -126.43 
-69.92 -180.77 48.61 145.75 205.85 178.74 -97.73 
-54.02 -192.33 50.41 116.38 n.a. n.a. -129.26 
-65.93 -182.95 45.58 144.31 208.62 -178.59 -95.46 
-54.76 -194.21 48.41 123.20 n.a. n.a. -126.18 
PD0145 -145.49 -102.11 74.49 115.65 173.04 -124.77 -99.75 
-71.69 -168.31 53.64 149.81 193.33 -118.17 -104.33 
PD0146 -144.77 -110.53 72.86 107.96 164.32 -102.19 -111.91 
-147.50 -121.58 98.71 113.15 172.10 -116.40 -133.80 
PD0155 -69.77 -172.96 42.57 141.22 202.83 -136.07 -101.70 
-70.40 -182.81 53.84 121.12 194.06 -130.01 -119.60 
PD0165 -63.15 -174.24 41.26 129.13 189.39 -106.93 -105.68 
-330.94 -180.05 299.10 147.11 177.05 -83.24 -105.15 
-69.64 -173.14 40.48 125.10 181.64 -93.17 -102.21 
-83.03 -160.47 49.23 133.06 183.82 -101.78 -106.02 
-79.61 -159.20 44.96 136.01 189.36 -112.34 -108.64 
-64.10 -166.24 38.26 132.11 181.35 -95.30 -104.54 
PD0192 -69.60 -224.20 48.26 141.38 178.63 -109.12 -111.01 
PD0200 -71.50 -202.23 56.89 147.81 185.70 -92.24 -122.07 
PD0219 -64.07 -181.08 53.36 85.84 192.50 -71.54 -160.85 
-54.09 -186.10 47.34 88.50 190.94 -72.67 -162.78 
-52.96 -184.28 42.97 88.06 186.55 -68.38 -160.58 
-71.67 -177.05 56.27 86.46 193.60 -73.89 -161.98 
PD0221 -47.87 -176.05 38.20 138.91 207.53 -108.29 -116.65 
PD0222 -141.12 -228.60 91.85 150.70 207.30 -150.25 -128.75 
PD0230 -333.52 -183.63 -48.11 156.85 174.66 -84.65 -99.47 
PD0231 -65.91 -161.57 40.80 139.19 177.56 -93.36 -102.72 
PD0251 -66.19 -193.95 5574 135.70 197.05 -123.92 -113.19 
-93-
(cont'd)  
a P Y S 8 C X  
PD0252 -55.97 -207.22 45.71 143.99 194.35 -134.85 -103.20 
PD0259 -45.11 -200.15 48.07 141.24 173.62 -95.60 -106.76 
-51.80 -197.96 46.24 137.45 175.37 -103.37 -100.86 
PD0270 -41.26 -163.17 22.91 149.25 191.79 -139.44 -108.65 
PD0286 -40.73 -197.44 49.09 140.94 192.57 -144.98 -94.35 
-37.66 -199.04 48.78 143.65 196.26 -121.32 -112.88 
-13.43 -242.35 46.20 140.35 204.76 -165.26 -105.16 
-67.57 -166.20 38.94 140.13 196.91 -145.82 -92.38 
PD0307 -78.84 -223.40 49.52 140.14 207.99 -128.15 -126.63 
-180.56 -123.25 151.75 92.78 196.44 -60.77 -158.18 
PD0309 -239.74 -123.21 181.32 129.10 206.84 -89.40 -151.36 
-49.90 -199.75 60.37 147.99 207.93 -120.36 -94.94 
PD0310 -53.89 -204.75 45.13 140.16 195.72 -121.55 -105.94 
PD0312 -47.96 -178.48 43.86 140.93 n.a. n.a. -114.14 
-49.77 -197.25 36.34 140.38 n.a. n.a. -87.86 
PD0316 -228.61 -188.68 177.14 144.90 180.82 -111.86 -113.01 
-85.94 -145.52 44.25 158.17 147.67 -136.26 -111.77 
PD0319 -73.77 -149.06 46.10 155.80 294.44 -233.06 -83.21 
PD0320 -67.34 -195.60 60.23 167.82 270.54 -206.81 -91.48 
PD0338 -45.98 -205.24 40.58 134.17 169.37 -98.56 -97.68 
PD0364 -8.23 -221.14 25.98 129.74 166.63 -101.31 -111.72 
PD0365 -333.21 -234.76 3.63 131.75 161.61 -100.10 -86.92 
PD0393 -62.53 -181.02 43.68 117.68 58.26 -308.11 -98.70 
-167.94 -153.21 60.20 151.50 314.87 -217.40 -84.67 
-81.88 -212.36 13.14 123.72 156.71 -90.34 -100.82 
-84.44 -164.96 65.94 107.13 160.95 -56.78 -123.53 
-89.13 -170.25 53.20 103.53 170.27 -74.53 -135.09 
PD0424 -48.37 -177.08 33.83 138.89 185.62 -99.05 -109.10 
-81.03 -155.83 44.37 145.27 188.66 -105.17 -94.62 
PD0429 -49.57 -167.74 40.44 137.75 189.12 -118.21 -100.50 
-39.14 -200.09 39.69 138.73 205.76 -158.69 -108.47 
-319.53 -209.10 321.03 151.35 189.73 -77.35 -91.35 
-113.92 -279.15 166.67 146.66 201.71 -90.37 -146.72 
PD0504 -50.27 -218.55 43.44 138.87 191.73 -93.26 -113.56 
-62.05 -179.90 36.44 140.66 199.53 -139.78 -93.56 
-94-
(cont'd)  
a P Y S 8 C X  
-40.42 -211.16 38.00 138.35 206.92 -164.87 -107.15 
PD0505 -55.67 -214.24 39.85 137.59 199.79 -98.62 -113.07 
-50.94 -194.24 31.94 134.59 200.08 -155.28 -97.84 
-67.68 -211.86 49.62 139.65 186.90 -91.02 -117.14 
-68.89 -175.69 43.54 140.39 195.25 -128.71 -100.74 
PDE003 -52.90 -191.87 58.45 138.32 221.72 -128.68 -113.80 
-67.38 -189.83 74.76 140.16 216.47 -122.86 -108.80 
PDE011 -68.78 -166.80 56.05 151.15 206.28 -142.30 -107.35 
PDE012 -69.91 -188.01 56.31 142.21 202.50 -127.09 -104.33 
-56.78 -177.64 48.89 141.39 184.44 -124.40 -102.10 
PDE0128 -78.19 -190.22 57.67 73.49 196.67 -64.32 -172.92 
-92.86 -177.49 71.48 76.53 219.43 -93.26 -176.20 
-59.63 -201.64 55.71 67.74 204.36 -61.52 -168.17 
-289.01 -198.60 61.98 73.15 204.04 -88.80 -177.18 
-236.53 -165.14 222.32 125.66 212.55 -82.66 -164.76 
(d) 5,-G ⑷ 
a p Y 5 8 C X  
Average value 
overall -86.67 177.79 60.82 124.16 196.03 -112.94 -119.54 
(273.33) (177.79) (60.82) (124.16) (196.03) (247.06) (240.46) 
NMR -64.45 226.89 56.94 133.06 179.55 -104.42 -121.37 
(295.55) (226.89) (56.94) (133.06) (179.55) (255.58) (238.63) 
X-Ray -89.05 172.53 61.24 123.21 198.17 -114.05 -119.35 
(270.95) (172.53) (61.24) (123.21) (198.17) (245.95) (240.65) 
Standard deviation 
overall 56.61 38.89 38.44 21.64 31.03 37.06 25.37 
NMR 0.69 69.43 5.67 18.08 12.21 8.85 4.10 
X-Ray 59.16 32.05 40.46 22.05 32.23 39.28 26.71 
-95-
(cont'd)  
a P Y S 8 C X  
NMR 
1KBD -63.72 186.60 52.36 142.47 187.18 -108.98 -118.80 
1LWA -65.08 307.05 63.29 112.21 165.46 -94.22 -126.10 
2KBD -64.55 187.01 55.19 144.49 186.00 -110.06 -119.22 
X-Ray 
PD0068 -82.52 167.90 56.72 130.70 229.62 -81.57 -92.56 
PD0095 -40.91 145.15 48.68 138.86 170.95 -86.19 -94.29 
-59.56 161.55 53.22 141.96 170.25 -82.05 -94.74 
PD0112 -50.09 157.71 51.05 113.72 n.a. n.a. -136.51 
-57.54 168.29 48.54 120.08 n.a. n.a. -127.11 
-57.47 170.99 50.91 117.13 n.a. n.a. -126.43 
-54.02 167.67 50.41 116.38 n.a. n.a. -129.26 
-54.76 165.79 48.41 123.20 n.a. n.a. -126.18 
PD0145 -145.49 257.89 74.49 115.65 173.04 -124.77 -99.75 
PD0146 -144.77 249.47 72.86 107.96 164.32 -102.19 -111.91 
PD0251 -74.61 170.64 52.63 135.95 195.79 -135.47 -103.68 
-66.19 166.05 55.74 135.70 197.05 -123.92 -113.19 
PD0252 -72.72 172.76 45.04 140.14 210.22 -149.12 -97.96 
-55.97 152.78 45.71 143.99 194.35 -134.85 -103.20 
PD0393 -167.94 206.79 60.20 151.50 314.87 -217.40 -84.67 
-81.88 147.64 13.14 123.72 156.71 -90.34 -100.82 
-84.44 195.04 65.94 107.13 160.95 -56.78 -123.53 
-89.13 189.75 53.20 103.53 170.27 -74.53 -135.09 
PD0429 -39.14 159.91 39.69 138.73 205.76 -158.69 -108.47 
-113.92 80.85 166.67 146.66 201.71 -90.37 -146.72 
PD0504 -62.05 180.10 36.44 140.66 199.53 -139.78 -93.56 
•40.42 148.84 38.00 138.35 206.92 -164.87 -107.15 
PD0505 -50.94 165.76 31.94 134.59 200.08 -155.28 -97.84 
-68.89 184.31 43.54 140.39 195.25 -128.71 -100.74 
PDE0128 -92.86 182.51 71.48 76.53 219.43 -93.26 -176.20 
-59.63 158.36 55.71 67.74 204.36 -61.52 -168.17 
-289.01 161.40 61.98 73.15 204.04 -88.80 -177.18 
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